var docs;if (!docs) docs =[]; docs["67"]={"6700":"<p><b>Title</b> MetFORMIN / Dalfampridine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> MetFORMIN may increase the serum concentration of Dalfampridine. Dalfampridine may increase the serum concentration of MetFORMIN. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased levels/adverse effects of dalfampridine (referred to as fampridine in Canada) and metformin when the two drugs are used concomitantly.</p> \n<p><b>Discussion</b> 4-aminopyridine is referred to as dalfampridine in the U.S. and fampridine in Canada. Fampridine Canadian product monograph recommends caution with concomitant use of metformin.<sup>1</sup> In contrast to the Canadian labeling recommendations, a similar warning is not found in dalfampridine U.S. product labeling.<sup>2</sup> Dalfampridine and metformin are Organic Cation Transporter 2 (OCT2) substrates. Following uptake into renal tubular cells via OCT2, dalfampridine and metformin undergo renal tubular secretion. Dalfampridine and metformin may compete for renal tubular uptake and systemic exposure of either drug could potentially be increased with concomitant use. Monitoring of patients receiving dalfampridine concomitantly with metformin may be warranted.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Product monograph. Fampyra (fampridine). Mississauga, Ontario: Biogen Idec Canada Inc., February 2012.</p>\n<p>2. Prescribing information. Ampyra (dalfampridine). Hawthorne, NY: Acorda Therapeutics Inc., January 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6701":"<p><b>Title</b> Pravastatin / Darunavir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Darunavir may increase the serum concentration of Pravastatin. This effect has been demonstrated with darunavir/ritonavir and may occur with darunavir/cobicistat. The individual contributions of darunavir, ritonavir, and cobicistat are unknown. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for signs and symptoms of pravastatin toxicity (e.g., myalgia, rhabdomyolysis, liver function test abnormalities, etc.) during concomitant treatment with darunavir/ritonavir or darunavir/cobicistat.</p> \n<p><b>Discussion</b> In a clinical study summarized in pravastatin prescribing information, coadministration of darunavir/ritonavir (600/100 mg twice daily for 7 days) increased pravastatin (40 mg single dose) maximum concentration and AUC by 63% and 81%, respectively.<sup>1</sup> The mechanism of this interaction is unclear. Darunavir and ritonavir could both inhibit P-glycoprotein mediated pravastatin transport and CYP3A4 mediated pravastatin metabolism. However, neither of these pathways is an established major determinant of pravastatin pharmacokinetics, and the protease inhibitor combination saquinavir/ritonavir (saquinavir also a CYP3A4/P-gp inhibitor) actually decreased pravastatin AUC by 50%,<sup>2</sup> suggesting that other pathways contribute to one or both of the interactions.<br><br>The product labeling for darunavir/cobicistat states that pravastatin concentrations may be increased with the combined use of darunavir/cobicistat and pravastatin.<sup>3</sup> Initiation of the lowest recommended pravastatin dose and careful titration while monitoring for safety is recommended when this combination is used. The mechanism for this possible interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Pravachol (pravastatin) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; July 2016.</p>\n<p>2. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. <i>AIDS</i>. 2002;16(4):569-577. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11873000\">[PubMed 11873000]</a></p>\n<p>3. Prezcobix (darunavir and cobicistat) [prescribing information]. Titusville, NJ: Janssen Therapeutics, Division of Janssen Products, LP; June 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6702":"<p><b>Title</b> Pravastatin / Nelfinavir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Nelfinavir may decrease the serum concentration of Pravastatin. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for reduced pravastatin pharmacologic effects/increased dose requirements in patients treated with nelfinavir.</p> \n<p><b>Discussion</b> In a clinical study of 14 healthy volunteers, coadministration of nelfinavir (1250 mg twice daily for 12 days) decreased pravastatin (40 mg daily for 3 days) maximum concentration and AUC by 40% and 47%, respectively.<sup>1</sup> The mechanism of this interaction is unclear. Similar decreases in pravastatin exposure were seen with coadministration of saquinavir/ritonavir in another clinical study,<sup>2</sup> but pravastatin AUC actually increased by 81% with coadministration of darunavir/ritonavir.<sup>3</sup> <br><br>Pravastatin had no apparent impact on exposure to nelfinavir or its active metabolite (M8) in a clinical study of healthy volunteers.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Aberg JA, Rosenkranz SL, Fichtenbaum CJ, et al, “Pharmacokinetic Interaction Between Nelfinavir and Pravastatin in HIV-Seronegative Volunteers: ACTG Study A5108,” <i>AIDS</i>, 2006, 20(5):725-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16514303\">[PubMed 16514303]</a></p>\n<p>2. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al, “Pharmacokinetic Interactions Between Protease Inhibitors and Statins in HIV Seronegative Volunteers: ACTG Study A5047,” <i>AIDS</i>, 2002, 16(4):569-77. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11873000\">[PubMed 11873000]</a></p>\n<p>3. Prescribing information. Pravachol (pravastatin). Princeton, NJ: Bristol-Myers Squibb Company, 2/2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6703":"<p><b>Title</b> Pravastatin / Saquinavir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Saquinavir may decrease the serum concentration of Pravastatin. This effect has only been demonstrated with saquinavir/ritonavir. The individual contributions of saquinavir and ritonavir are unknown. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for reduced pravastatin pharmacologic effects/increased dose requirements in patients treated with saquinavir/ritonavir.</p> \n<p><b>Discussion</b> In a clinical study of 13 healthy volunteers, coadministration of saquinavir/ritonavir (400/400 mg twice daily for 15 days) decreased the AUC of pravastatin (40 mg daily for 4 days) by 50%.<sup>1</sup> The mechanism of this interaction is unknown. In another clinical study, the protease inhibitor combination darunavir/ritonavir actually increased pravastatin AUC by 81%.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al, “Pharmacokinetic Interactions Between Protease Inhibitors and Statins in HIV Seronegative Volunteers: ACTG Study A5047,” <i>AIDS</i>, 2002, 16(4):569-77. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11873000\">[PubMed 11873000]</a></p>\n<p>2. Prescribing information. Pravachol (pravastatin). Princeton, NJ: Bristol-Myers Squibb Company, 2/2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6704":"<p><b>Title</b> MetyroSINE / Alcohol (Ethyl)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Alcohol (Ethyl) may enhance the sedative effect of MetyroSINE. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for enhanced sedative effects of alcohol in patients receiving metyrosine, and warn patients about potential hazards of engaging in activities requiring mental alertness and/or motor coordination (e.g., driving).</p> \n<p><b>Discussion</b> According to metyrosine prescribing information, the sedative effects of metyrosine may be additive with those of alcohol and CNS depressants.<sup>1</sup> Moderate to severe sedation occurs in almost all patients receiving metyrosine, and is most evident in the first week following metyrosine initiation or dose increase. Patients prescribed metyrosine should be warned about potential hazards of engaging in activities requiring mental alertness and/or motor coordination (e.g., driving).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Demser (metyrosine). Lawrenceville, NJ: Aton Pharma, Inc., February 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6705":"<p><b>Title</b> MetyroSINE / CNS Depressants</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CNS Depressants may enhance the sedative effect of MetyroSINE. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for enhanced sedative effects of CNS depressants in patients receiving metyrosine, and warn patients about potential hazards of engaging in activities requiring mental alertness and/or motor coordination (e.g., driving).</p>\n<div>\n <p><b>CNS Depressants Interacting Members</b> Acrivastine, Afloqualone, Alcohol (Ethyl), Alfentanil, ALPRAZolam, Amisulpride, Amitriptyline, Amobarbital, Amoxapine, ARIPiprazole, ARIPiprazole Lauroxil, Asenapine, Baclofen, Benperidol, Benzhydrocodone, Bilastine, Blonanserin, Brexpiprazole, Brimonidine (Ophthalmic), Brivaracetam, Bromazepam, Bromperidol, Brompheniramine, Buclizine, Buprenorphine, BusPIRone, Butabarbital, Butalbital, Butorphanol, CarBAMazepine, Carbinoxamine, Cariprazine, Carisoprodol, Cetirizine (Systemic), Chloral Betaine, Chloral Hydrate, ChlordiazePOXIDE, Chlormethiazole, Chlorpheniramine, ChlorproMAZINE, Chlorzoxazone, Cinnarizine, Clemastine, CloBAZam, ClomiPRAMINE, ClonazePAM, CloNIDine, Clorazepate, Clothiapine, CloZAPine, Codeine, Cyclizine, Cyclobenzaprine, Cyproheptadine, Dantrolene, Desflurane, Desipramine, Desloratadine, Deutetrabenazine, Dexbrompheniramine, Dexchlorpheniramine, DiazePAM, Difenoxin, Dihydrocodeine, DimenhyDRINATE, Dimethindene (Systemic), DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Diphenoxylate, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Efavirenz, Emedastine (Systemic), Entacapone, Eperisone, Estazolam, Eszopiclone, Ethosuximide, Ethotoin, Ethyl Loflazepate, Etizolam, Ezogabine, Felbamate, FentaNYL, Fexofenadine, Flibanserin, Flunarizine, Flunitrazepam, Flupentixol, FluPHENAZine, Flurazepam, Fosphenytoin, Gabapentin, Gabapentin Enacarbil, Glutethimide, GuanFACINE, Haloperidol, Halothane, Heroin, HYDROcodone, HYDROmorphone, HydrOXYzine, Iloperidone, Imipramine, Isoflurane, Ketamine, Ketotifen (Systemic), LamoTRIgine, LevETIRAcetam, Levocetirizine, Levorphanol, Lofepramine, Loprazolam, Loratadine, LORazepam, Lormetazepam, Loxapine, Lurasidone, Maprotiline, Meclizine, Melitracen [INT], Meperidine, Meprobamate, Meptazinol, Mequitazine, Metaxalone, Methadone, Methocarbamol, Methohexital, Methotrimeprazine, Methoxyflurane, Methsuximide, Mianserin, Midazolam, Mirtazapine, Molindone, Morphine (Liposomal), Morphine (Systemic), Moxonidine, Nalbuphine, Nalfurafine, Nefopam, Nitrazepam, Nitrous Oxide, Nordazepam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Opium, Opium Tincture, Orphenadrine, Oxatomide, Oxazepam, Oxomemazine, OxyCODONE, OxyMORphone, Paliperidone, Paraldehyde, Paregoric, Pentazocine, PENTobarbital, Perampanel, Periciazine, Perphenazine, Pheniramine, PHENobarbital, Phenyltoloxamine, Phenytoin, Pholcodine, Pimozide, Pipamperone [INT], Pipotiazine, Pizotifen, Pomalidomide, Prazepam, Pregabalin, Primidone, Prochlorperazine, Promazine, Promethazine, Propofol, Protriptyline, Pyrilamine (Systemic), Quazepam, QUEtiapine, Ramelteon, Remifentanil, Reserpine, Rilmenidine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Secobarbital, Sevoflurane, Sodium Oxybate, Stiripentol, SUFentanil, Sulpiride, Suvorexant, Tapentadol, Tasimelteon, Temazepam, Tetrabenazine, Thalidomide, Thiopental, Thioridazine, Thiothixene, Thonzylamine, TiaGABine, TiZANidine, Tofisopam, Tolcapone, Topiramate, TraMADol, Triazolam, Trifluoperazine, Trimeprazine, Trimipramine, Triprolidine, Valerian, Vigabatrin, Zaleplon, Ziconotide, Ziprasidone, Zolpidem, Zonisamide, Zopiclone, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> According to metyrosine prescribing information, the sedative effects of metyrosine may be additive with those of alcohol and CNS depressants.<sup>1</sup> Moderate to severe sedation occurs in almost all patients receiving metyrosine, and is most evident in the first week following metyrosine initiation or dose increase. Patients prescribed metyrosine should be warned about potential hazards of engaging in activities requiring mental alertness and/or motor coordination (e.g., driving).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Demser (metyrosine). Lawrenceville, NJ: Aton Pharma, Inc., February 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6706":"<p><b>Title</b> Selective Serotonin Reuptake Inhibitors / MetyroSINE</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> MetyroSINE may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients receiving metyrosine and selective serotonin reuptake inhibitors for development of extrapyramidal symptoms, which may be additive with the combination of these agents.</p>\n<div>\n <p><b>Selective Serotonin Reuptake Inhibitors Interacting Members</b> Citalopram, Dapoxetine, Escitalopram, FLUoxetine, FluvoxaMINE, PARoxetine, Sertraline, Vilazodone, Vortioxetine</p>\n</div> \n<p><b>Discussion</b> Per metyrosine prescribing information, metyrosine should be administered with caution in patients receiving certain other drugs associated with extrapyramidal symptoms such as phenothiazines and haloperidol.<sup>1</sup><br> <br>Metyrosine is presumed to induce extrapyramidal symptoms primarily via inhibition of catecholamine synthesis, leading to decreased central dopamine concentrations and reduced stimulation of nigrostriatal and/or striatopallidal pathways that regulate output from the basal ganglia controlling movement.<sup>2</sup> Based on this presumed mechanism, additive effects could be expected with most or all other drugs that are associated with development of extrapyramidal symptoms, including selective serotonin reuptake inhibitors.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Demser (metyrosine). Lawrenceville, NJ: Aton Pharma, Inc., February 2010.</p>\n<p>2. Gerfen CR, “Molecular Effects of Dopamine on Striatal-Projection Pathways,” <i>Trends Neurosci</i>, 2000, 23(Suppl):S64-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11052222\">[PubMed 11052222]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6707":"<p><b>Title</b> Tricyclic Antidepressants / MetyroSINE</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> MetyroSINE may enhance the adverse/toxic effect of Tricyclic Antidepressants. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients receiving metyrosine and tricyclic antidepressants for development of extrapyramidal symptoms, which may be additive with the combination of these agents.</p>\n<div>\n <p><b>Tricyclic Antidepressants Interacting Members</b> Amitriptyline, Amoxapine, ClomiPRAMINE, Desipramine, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Imipramine, Lofepramine, Melitracen [INT], Nortriptyline, Protriptyline, Trimipramine</p>\n</div> \n<p><b>Discussion</b> Per metyrosine prescribing information, metyrosine should be administered with caution in patients receiving certain other drugs associated with extrapyramidal symptoms such as phenothiazines and haloperidol.<sup>1</sup><br> <br>Metyrosine is presumed to induce extrapyramidal symptoms primarily via inhibition of catecholamine synthesis, leading to decreased central dopamine concentrations and reduced stimulation of nigrostriatal and/or striatopallidal pathways that regulate output from the basal ganglia controlling movement.<sup>2</sup> Based on this presumed mechanism, additive effects could be expected with most or all other drugs that are associated with development of extrapyramidal symptoms, including tricyclic antidepressants.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Demser (metyrosine). Lawrenceville, NJ: Aton Pharma, Inc., February 2010.</p>\n<p>2. Gerfen CR, “Molecular Effects of Dopamine on Striatal-Projection Pathways,” <i>Trends Neurosci</i>, 2000, 23(Suppl):S64-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11052222\">[PubMed 11052222]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6708":"<p><b>Title</b> Antipsychotic Agents / MetyroSINE</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> MetyroSINE may enhance the adverse/toxic effect of Antipsychotic Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients receiving metyrosine and antipsychotics for development of extrapyramidal symptoms and sedation, which may be additive with the combination of these agents. Warn patients about potential hazards of engaging in activities requiring mental alertness and/or motor coordination (e.g., driving).</p>\n<div>\n <p><b>Antipsychotic Agents Interacting Members</b> Amisulpride, ARIPiprazole, ARIPiprazole Lauroxil, Asenapine, Benperidol, Blonanserin, Brexpiprazole, Bromperidol, Cariprazine, ChlorproMAZINE, Clothiapine, CloZAPine, Droperidol, Flupentixol, FluPHENAZine, Haloperidol, Iloperidone, Loxapine, Lurasidone, Methotrimeprazine, Molindone, OLANZapine, Paliperidone, Periciazine, Perphenazine, Pimozide, Pipamperone [INT], Pipotiazine, Prochlorperazine, Promazine, QUEtiapine, RisperiDONE, Sulpiride, Thioridazine, Thiothixene, Trifluoperazine, Ziprasidone, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> Per metyrosine prescribing information, metyrosine should be administered with caution in patients receiving certain other drugs associated with extrapyramidal symptoms such as phenothiazines and haloperidol.<sup>1</sup> Metyrosine is presumed to induce extrapyramidal symptoms primarily via inhibition of catecholamine synthesis, leading to decreased central dopamine concentrations and reduced stimulation of nigrostriatal and/or striatopallidal pathways that regulate output from the basal ganglia controlling movement.<sup>2</sup> Based on this presumed mechanism, additive effects could be expected with most or all other drugs that are associated with development of extrapyramidal symptoms, including antipsychotics.<br><br>In addition to the above mechanism of interaction, the sedative effects of metyrosine may be additive with those of CNS depressants such as antipsychotics.<sup>1</sup> Moderate to severe sedation occurs in almost all patients receiving metyrosine, and is most evident in the first week following metyrosine initiation or dose increase. Patients prescribed metyrosine should be warned about potential hazards of engaging in activities requiring mental alertness and/or motor coordination (e.g., driving).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Demser (metyrosine). Lawrenceville, NJ: Aton Pharma, Inc., February 2010.</p>\n<p>2. Gerfen CR, “Molecular Effects of Dopamine on Striatal-Projection Pathways,” <i>Trends Neurosci</i>, 2000, 23(Suppl):S64-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11052222\">[PubMed 11052222]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6709":"<p><b>Title</b> Droperidol / MetyroSINE</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> MetyroSINE may enhance the adverse/toxic effect of Droperidol. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients receiving metyrosine and droperidol for development of extrapyramidal symptoms and sedation, which may be additive with the combination of these agents. Warn patients about potential hazards of engaging in activities requiring mental alertness and/or motor coordination (e.g., driving).</p> \n<p><b>Discussion</b> Per metyrosine prescribing information, metyrosine should be administered with caution in patients receiving certain other drugs associated with extrapyramidal symptoms such as phenothiazines and haloperidol.<sup>1</sup> Metyrosine is presumed to induce extrapyramidal symptoms primarily via inhibition of catecholamine synthesis, leading to decreased central dopamine concentrations and reduced stimulation of nigrostriatal and/or striatopallidal pathways that regulate output from the basal ganglia controlling movement.<sup>2</sup> Based on this presumed mechanism, additive effects could be expected with most or all other drugs that are associated with development of extrapyramidal symptoms, including droperidol.<br><br>In addition to the above mechanism of interaction, the sedative effects of metyrosine may be additive with those of CNS depressants such as droperidol.<sup>1</sup> Moderate to severe sedation occurs in almost all patients receiving metyrosine, and is most evident in the first week following metyrosine initiation or dose increase. Patients prescribed metyrosine should be warned about potential hazards of engaging in activities requiring mental alertness and/or motor coordination (e.g., driving).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Demser (metyrosine). Lawrenceville, NJ: Aton Pharma, Inc., February 2010.</p>\n<p>2. Gerfen CR, “Molecular Effects of Dopamine on Striatal-Projection Pathways,” <i>Trends Neurosci</i>, 2000, 23(Suppl):S64-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11052222\">[PubMed 11052222]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6710":"<p><b>Title</b> Promethazine / MetyroSINE</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> MetyroSINE may enhance the adverse/toxic effect of Promethazine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients receiving metyrosine and promethazine for development of extrapyramidal symptoms and sedation, which may be additive with the combination of these agents. Warn patients about potential hazards of engaging in activities requiring mental alertness and/or motor coordination (e.g., driving).</p> \n<p><b>Discussion</b> Per metyrosine prescribing information, metyrosine should be administered with caution in patients receiving certain other drugs associated with extrapyramidal symptoms such as phenothiazines and haloperidol.<sup>1</sup> Metyrosine is presumed to induce extrapyramidal symptoms primarily via inhibition of catecholamine synthesis, leading to decreased central dopamine concentrations and reduced stimulation of nigrostriatal and/or striatopallidal pathways that regulate output from the basal ganglia controlling movement.<sup>2</sup> Based on this presumed mechanism, additive effects could be expected with most or all other drugs that are associated with development of extrapyramidal symptoms, including promethazine.<br><br>In addition to the above mechanism of interaction, the sedative effects of metyrosine may be additive with those of CNS depressants such as promethazine.<sup>1</sup> Moderate to severe sedation occurs in almost all patients receiving metyrosine, and is most evident in the first week following metyrosine initiation or dose increase. Patients prescribed metyrosine should be warned about potential hazards of engaging in activities requiring mental alertness and/or motor coordination (e.g., driving).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Demser (metyrosine). Lawrenceville, NJ: Aton Pharma, Inc., February 2010.</p>\n<p>2. Gerfen CR, “Molecular Effects of Dopamine on Striatal-Projection Pathways,” <i>Trends Neurosci</i>, 2000, 23(Suppl):S64-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11052222\">[PubMed 11052222]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6711":"<p><b>Title</b> Tetrabenazine / MetyroSINE</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> MetyroSINE may enhance the adverse/toxic effect of Tetrabenazine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients receiving metyrosine and tetrabenazine for development of extrapyramidal symptoms and sedation, which may be additive with the combination of these agents. Warn patients about potential hazards of engaging in activities requiring mental alertness and/or motor coordination (e.g., driving).</p> \n<p><b>Discussion</b> Per metyrosine prescribing information, metyrosine should be administered with caution in patients receiving certain other drugs associated with extrapyramidal symptoms such as phenothiazines and haloperidol.<sup>1</sup> Metyrosine is presumed to induce extrapyramidal symptoms primarily via inhibition of catecholamine synthesis, leading to decreased central dopamine concentrations and reduced stimulation of nigrostriatal and/or striatopallidal pathways that regulate output from the basal ganglia controlling movement.<sup>2</sup> Based on this presumed mechanism, additive effects could be expected with most or all other drugs that are associated with development of extrapyramidal symptoms, including tetrabenazine.<br><br>In addition to the above mechanism of interaction, the sedative effects of metyrosine may be additive with those of CNS depressants such as tetrabenazine.<sup>1</sup> Moderate to severe sedation occurs in almost all patients receiving metyrosine, and is most evident in the first week following metyrosine initiation or dose increase. Patients prescribed metyrosine should be warned about potential hazards of engaging in activities requiring mental alertness and/or motor coordination (e.g., driving).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Demser (metyrosine). Lawrenceville, NJ: Aton Pharma, Inc., February 2010.</p>\n<p>2. Gerfen CR, “Molecular Effects of Dopamine on Striatal-Projection Pathways,” <i>Trends Neurosci</i>, 2000, 23(Suppl):S64-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11052222\">[PubMed 11052222]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6712":"<p><b>Title</b> Metoclopramide / MetyroSINE</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> MetyroSINE may enhance the adverse/toxic effect of Metoclopramide. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Seek alternatives to this combination when possible. Monitor patients receiving metoclopramide with metyrosine for development of extrapyramidal symptoms.</p> \n<p><b>Discussion</b> The use of metoclopramide in combination with other agents associated with development of extrapyramidal reactions such as tardive dyskinesia should be avoided per metoclopramide prescribing information.<sup>1</sup><br><br>Dopaminergic activity within the nigrostriatal pathway (at dopamine D1 receptors) and striatopallidal pathway (at dopamine D2 receptors) regulates output from the basal ganglia which controls movement.<sup>2</sup> Metoclopramide inhibits central D2 receptors, which may cause an imbalance in dopaminergic activity between the nigrostriatal and striatopallidal pathways leading to movement-related side effects.<sup>3</sup> Other medications that inhibit central dopaminergic activity either directly (e.g. antipsychotics) or indirectly (e.g. serotonergic antidepressants) may increase the likelihood of serious movement-related side effects in patients receiving metoclopramide. Metyrosine has been associated with development of extrapyramidal symptoms, likely as a result of its inhibitory effects on catecholamine synthesis.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Metozolv (metoclopramide HCl). Morrisville, North Carolina: Salix Pharmaceuticals, September 2009.</p>\n<p>2. Gerfen CR, “Molecular Effects of Dopamine on Striatal-Projection Pathways,” <i>Trends Neurosci</i>, 2000, 23(Suppl):S64-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11052222\">[PubMed 11052222]</a></p>\n<p>3. Rao AS and Camilleri M, “Review Article: Metoclopramide and Tardive Dyskinesia,” <i>Aliment Pharmacol Ther</i>, 2010, 31(1):11-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19886950\">[PubMed 19886950]</a></p>\n<p>4. Prescribing information. Demser (metyrosine). Lawrenceville, NJ: Aton Pharma, Inc., February 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6713":"<p><b>Title</b> Mebendazole / Cimetidine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cimetidine may increase the serum concentration of Mebendazole. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased mebendazole levels/effects with concomitant use of cimetidine.</p> \n<p><b>Discussion</b> In 7 subjects with hydatid disease, mean mebendazole maximum concentrations (Cmax) increased ~50% after 3 weeks of concomitant mebendazole (dose not provided) and cimetidine (1000 mg/day).<sup>1</sup> In 8 subjects with peptic ulcer (n=5) or hydatid disease (n=3), coadministration of mebendazole 1500 mg on day 0 and 30 (peptic ulcer group) or daily x4 weeks (hydatid disease group) and cimetidine (400 mg TID x4 weeks) increased mean mebendazole Cmax ~48%.<sup>2</sup> In the 3 subjects with previously unresponsive hydatid disease, a complete resolution of hepatic cysts was observed after 4 weeks of concomitant therapy leading the authors to suggest that concomitant therapy may be of benefit in patients failing to achieve adequate serum and intracystic mebendazole concentrations in spite of dose adjustments. Some authors however suggest that the change in mebendazole concentrations observed with concomitant use of cimetidine are too small to be of therapeutic relevance.<sup>1</sup> Cimetidine may inhibit the hepatic metabolism of mebendazole. Monitoring of mebendazole serum concentrations is recommended with concomitant use of the drugs, particularly with prolonged therapy.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Luder PJ, Siffert B, Witassek F, et al, “Treatment of Hydatid Disease with High Oral Doses of Mebendazole. Long-Term Follow-Up of Plasma Mebendazole Levels and Drug Interactions,” <i>Eur J Clin Pharmacol</i>, 1986, 31(4):443-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3816925\">[PubMed 3816925]</a></p>\n<p>2. Bekhti A and Pirotte J, “Cimetidine increases serum mebendazole concentrations. Implications for treatment of hepatic hydatid cysts,” <i>Br J Clin Pharmacol</i>, 1987, 24(3):390-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3663452\">[PubMed 3663452]</a></p>\n<p>3. Product monograph. Vermox (mebendazole). Toronto, Ontario: Janssen Inc., April 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6720":"<p><b>Title</b> AtorvaSTATin / CycloSPORINE (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CycloSPORINE (Systemic) may increase the serum concentration of AtorvaSTATin. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Atorvastatin labeling states that concurrent use of cyclosporine and atorvastatin should be avoided due to an increased risk for atorvastatin-related toxicities such as myopathy and rhabdomyolysis. Consider changing to a statin that is less sensitive to this interaction (eg, pravastatin or fluvastatin) or to an alternative type of LDL-lowering medication. If atorvastatin and cyclosporine are coadministered, monitor creatinine kinase and for signs and symptoms of muscle-related toxicity.</p> \n<p><b>Discussion</b> According to the atorvastatin prescribing information, concurrent use with cyclosporine should be avoided.<sup>1</sup> At least one published case report describes rhabdomyolysis in a patient who received atorvastatin (10 mg/day) and cyclosporine (125 mg/day) concomitantly.<sup>2</sup> The atorvastatin AUC and maximum serum concentration (Cmax) were increased an average of 8.7- and 10.7-fold, respectively, when atorvastatin (10 mg/day for 28 days) was given with cyclosporine (5.2 mg/kg/day).<sup>1</sup> Total HMG-CoA reductase inhibitor activity was an average of 6-fold higher (vs. historic controls) among 21 patients treated with cyclosporine who had received atorvastatin (10 mg/day for 4 weeks).<sup>3</sup> An American Heart Association scientific statement recommends close monitoring of creatinine kinase and for signs or symptoms of muscle-related toxicity if cyclosporine and doses of atorvastatin greater than 10 mg daily are coadministered.<sup>4</sup><br><br>This interaction is likely the result of both cyclosporine inhibition of the CYP3A-mediated metabolism of atorvastatin and cyclosporine inhibition of the OATP1B1/SLCO1B1-mediated hepatic uptake of atorvastatin.<sup>5</sup><br><br>Conversely, atorvastatin appears to have little impact on cyclosporine concentrations. Although one small study reported that 4 of 10 patients receiving the combination experienced a 25% or greater increase in cyclosporine concentrations after starting atorvastatin,<sup>6</sup> several other studies have reported a smaller than 10% change in cyclosporine concentrations with concurrent atorvastatin.<sup>3,7,8</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Lipitor (atorvastatin) [prescribing information]. New York, NY: Pfizer Inc; June 2017.</p>\n<p>2. Maltz HC, Balog DL Cheigh JS. Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine. <i>Ann Pharmacother</i>. 1999;33(11):1176-1179. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10573315\">[PubMed 10573315]</a></p>\n<p>3. Asberg A, Hartmann A, Fjeldsa E, et al. Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients. <i>Am J Transplant</i>. 2001;1(4):382-386. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12099384\">[PubMed 12099384]</a></p>\n<p>4. Wiggins BS, Saseen JJ, Page RL 2nd, et al. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association. <i>Circulation</i>. 2016;134(21):e468-e495. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27754879\">[PubMed 27754879]</a></p>\n<p>5. Amundsen R, Christensen H, Zabihyan B, et al. Cyclosporine A, but not tacrolimus, shows relevant inhibition of organic anion-transporting protein 1B1-mediated transport of atorvastatin. <i>Drug Metab Dispos</i>. 2010;38(9):1499-1504. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20519340\">[PubMed 20519340]</a></p>\n<p>6. Renders L, Mayer-Kadner I, Koch C, et al. Efficacy and drug interactions of the new HMG-CoA reductase inhibitors cerivastatin and atorvastatin in CsA-treated renal transplant recipients. <i>Nephrol Dial Transplant</i>. 2001;16(1):141-146. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11209008\">[PubMed 11209008]</a></p>\n<p>7. Taylor PJ, Kubler PA, Lynch SV, et al. Effect of atorvastatin on cyclosporine pharmacokinetics in liver transplant recipients. <i>Ann Pharmacother</i>. 2004;38(2):205-208. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14742751\">[PubMed 14742751]</a></p>\n<p>8. Hermann M, Asberg A, Christensen H, et al. Atorvastatin does not affect the pharmacokinetics of cyclosporine in renal transplant recipients. <i>Eur J Clin Pharmacol</i>. 2005;61(1):59-62. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15711834\">[PubMed 15711834]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6721":"<p><b>Title</b> Fluvastatin / CycloSPORINE (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CycloSPORINE (Systemic) may increase the serum concentration of Fluvastatin. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Limit fluvastatin to 20 mg twice daily in patients who are also receiving cyclosporine. Monitor for toxic effects (e.g., myalgia, myopathy, rhabdomyolysis) of fluvastatin if cyclosporine is being received/dose increased, or decreased effects if cyclosporine is discontinued/dose decreased.</p> \n<p><b>Discussion</b> According to the fluvastatin prescribing information, the fluvastatin dose should be limited to 20 mg twice daily in patients being treated with cyclosporine.<sup>1</sup> Several studies have reported increases in fluvastatin AUC by 90% to approximately 3-fold with concurrent cyclosporine.<sup>1,2,3</sup> The corresponding fluvastatin maximum serum concentration (Cmax) was increased an average of 30% to 6-fold.<sup>1,2</sup><br><br>This interaction is likely the result of cyclosporine inhibition of the OATP1B1/SLCO1B1-mediated hepatic uptake of fluvastatin.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Lescol (fluvastatin). East Hanover, NJ: Novartis Pharmaceuticals Corporation, February 2012.</p>\n<p>2. Park JW, Siekmeier R, Lattke P, et al, “Pharmacokinetics and Pharmacodynamics of Fluvastatin in Heart Transplant Recipients Taking Cyclosporine A,” <i>J Cardiovasc Pharmacol Ther</i>, 2001, 6(4):351-61. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11907637\">[PubMed 11907637]</a></p>\n<p>3. Holdaas H, Hagen E, Asberg A, et al, “Evaluation of the Pharmacokinetic Interaction Between Fluvastatin XL and Cyclosporine in Renal Transplant Recipients,” <i>Int J Clin Pharmacol Ther</i>, 2006, 44(4):163-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16625985\">[PubMed 16625985]</a></p>\n<p>4. Amundsen R, Christensen H, Zabihyan B, et al, “Cyclosporine A, but Not Tacrolimus, Shows Relevant Inhibition of Organic Anion-Transporting Protein 1B1-Mediated Transport of Atorvastatin,” <i>Drug Metab Dispos</i>, 2010, 38(9):1499-504. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20519340\">[PubMed 20519340]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6722":"<p><b>Title</b> Lovastatin / CycloSPORINE (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CycloSPORINE (Systemic) may increase the serum concentration of Lovastatin. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Concurrent use of lovastatin with cyclosporine should be avoided. Consider changing to a statin that is less sensitive to this interaction (e.g., pravastatin or fluvastatin) or to an alternative type of LDL-lowering medication.</p> \n<p><b>Discussion</b> According to the lovastatin prescribing information, concurrent use with cyclosporine should be avoided.<sup>1</sup> Several published case reports describe myopathy or rhabdomyolysis in patients who received this combination.<sup>2,3,4,5</sup> Lovastatin concentrations were an average of 5- to 20-fold higher with concurrent cyclosporine in several clinical studies.<sup>1,3,6</sup> Other studies have similarly reported greater lipid-lowering effects of lovastatin when given with cyclosporine.<sup>7,8</sup><br><br>This interaction is likely the result of both cyclosporine inhibition of the CYP3A-mediated metabolism of lovastatin and cyclosporine inhibition of the OATP1B1/SLCO1B1-mediated hepatic uptake of lovastatin.<sup>9</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Mevacor (lovastatin). Whitehouse Station, NJ: Merck &amp; Co., Inc., 02/2012.</p>\n<p>2. Corpier CL, Jones PH, Suki WN, et al, “Rhabdomyolysis and Renal Injury with Lovastatin Use. Report of Two Cases in Cardiac Transplant Recipients,” <i>JAMA</i>, 1988, 260(2):239-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3290520\">[PubMed 3290520]</a></p>\n<p>3. Kobashigawa JA, Murphy FL, Stevenson LW, et al, “Low-Dose Lovastatin Safely Lowers Cholesterol After Cardiac Transplantation,” <i>Circulation</i>, 1990, 82(5 Suppl):IV281-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2225417\">[PubMed 2225417]</a></p>\n<p>4. Gullestad L, Nordal KP, Berg KJ, et al, “Interaction Between Lovastatin and Cyclosporine A After Heart and Kidney Transplantation,” <i>Transplant Proc</i>, 1999, 31(5):2163-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10456002\">[PubMed 10456002]</a></p>\n<p>5. Alejandro DS, Petersen J, “Myoglobinuric Acute Renal Failure in a Cardiac Transplant Patient Taking Lovastatin and Cyclosporine,” <i>J Am Soc Nephrol</i>, 1994, 5(2):153-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7993994\">[PubMed 7993994]</a></p>\n<p>6. Olbricht C, Wanner C, Eisenhauer T, et al, “Accumulation of Lovastatin, but Not Pravastatin, in the Blood of Cyclosporine-Treated Kidney Graft Patients after Multiple Doses,” <i>Clin Pharmacol Ther</i>, 1997, 62(3):311-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9333107\">[PubMed 9333107]</a></p>\n<p>7. Anguita M, Alonso-Pulpon L, et al, “Comparison of the Effectiveness of Lovastatin Therapy for Hypercholesterolemia After Heart Transplantation Between Patients with and without Pretransplant Atherosclerotic Coronary Artery Disease,” <i>Am J Cardiol</i>, 1994, 74(8):776-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7942548\">[PubMed 7942548]</a></p>\n<p>8. Cheung AK, DeVault GA Jr, Gregory MC, “A Prospective Study on Treatment of Hypercholesterolemia with Lovastatin in Renal Transplant Patients Receiving Cyclosporine,” <i>J Am Soc Nephrol</i>, 1993, 3(12):1884-91. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8338920\">[PubMed 8338920]</a></p>\n<p>9. Amundsen R, Christensen H, Zabihyan B, et al, “Cyclosporine A, but Not Tacrolimus, Shows Relevant Inhibition of Organic Anion-Transporting Protein 1B1-Mediated Transport of Atorvastatin,” <i>Drug Metab Dispos</i>, 2010, 38(9):1499-504. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20519340\">[PubMed 20519340]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6723":"<p><b>Title</b> Pravastatin / CycloSPORINE (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CycloSPORINE (Systemic) may increase the serum concentration of Pravastatin. Pravastatin may increase the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Limit pravastatin to 20 mg/day in patients who are also receiving cyclosporine. Monitor for toxic effects (eg, myalgia, myopathy, rhabdomyolysis) of pravastatin if cyclosporine is being received/dose increased, or decreased effects if cyclosporine is discontinued/dose decreased.</p> \n<p><b>Discussion</b> According to both the pravastatin prescribing information and a scientific statement from the American Heart Association, the pravastatin dose should be limited to 20 mg/day in patients being treated with cyclosporine.<sup>1,2</sup> In several studies pravastatin concentrations have been approximately 3- to 12-fold higher with concurrent cyclosporine.<sup>1,2,3,4</sup><br><br>This interaction is likely the result of cyclosporine inhibition of the OATP1B1/SLCO1B1-mediated hepatic uptake of pravastatin.<sup>5</sup><br><br>Of note, one case report describes elevated cyclosporine concentrations following initiation of pravastatin,<sup>6</sup> and a follow-up in vitro study by the same group reported that pravastatin was able to inhibit cyclosporine transport via MRP2, potentially explaining the case observations. In contrast, in addition to the many studies describing safe coadministration, a study of 31 post-renal transplant patients reported that pravastatin did not significantly alter cyclosporine concentrations.<sup>7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Pravachol (pravastatin) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; July 2016.</p>\n<p>2. Wiggins BS, Saseen JJ, Page RL 2nd, et al. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association. <i>Circulation</i>. 2016;134(21):e468-e495. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27754879\">[PubMed 27754879]</a></p>\n<p>3. Olbricht C, Wanner C, Eisenhauer T, et al. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. <i>Clin Pharmacol Ther</i>. 1997;62(3):311-321. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9333107\">[PubMed 9333107]</a></p>\n<p>4. Park JW, Siekmeier R, Merz M, et al. Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A. <i>Int J Clin Pharmacol Ther</i>. 2002;40(10):439-450. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12395976\">[PubMed 12395976]</a></p>\n<p>5. Amundsen R, Christensen H, Zabihyan B, et al. Cyclosporine A, but not tacrolimus, shows relevant inhibition of organic anion-transporting protein 1B1-mediated transport of atorvastatin. <i>Drug Metab Dispos</i>. 2010;38(9):1499-1504. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20519340\">[PubMed 20519340]</a></p>\n<p>6. Kato R, Nishide M, Kozu C, et al. Is cyclosporine A transport inhibited by pravastatin via multidrug resistant protein 2? <i>Eur J Clin Pharmacol</i>. 2010;66(2):153-158. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19823813\">[PubMed 19823813]</a></p>\n<p>7. Capone D, Stanziale P, Gentile A, et al. Effects of simvastatin and pravastatin on hyperlipidemia and cyclosporin blood levels in renal transplant recipients. <i>Am J Nephrol</i>. 1999; 19(3):411-415. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10393380\">[PubMed 10393380]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6724":"<p><b>Title</b> Rosuvastatin / CycloSPORINE (Systemic)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: Canadian labeling lists this combination as contraindicated. US labeling recommends limiting rosuvastatin dose to a maximum of 5 mg/day.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CycloSPORINE (Systemic) may increase the serum concentration of Rosuvastatin. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Limit rosuvastatin to 5 mg/day in patients who are also receiving cyclosporine. Canadian labeling contraindicates concomitant use of rosuvastatin with cyclosporine. Monitor for toxic effects (e.g., myalgia, myopathy, rhabdomyolysis) of rosuvastatin if cyclosporine is being received/dose increased, or decreased effects if cyclosporine is discontinued/dose decreased.</p> \n<p><b>Discussion</b> The US prescribing information for rosuvastatin recommends limiting the rosuvastatin dose to 5 mg/day,<sup>1</sup> while the Canadian product monograph contraindicated concurrent use of rosuvastatin with cyclosporine.<sup>2</sup> The average AUC and maximum serum concentration (Cmax) were 7.1- and 10.6-fold higher, respectively, in post-transplant patients receiving cyclosporine (n=10) than in healthy volunteers (historical, n=21).<sup>3</sup> Animal data similarly show increased rosuvastatin concentrations and decreased hepatic extraction with concurrent cyclosporine.<sup>4</sup><br><br>This interaction is likely the result of cyclosporine inhibition of the OATP1B1/SLCO1B1-mediated hepatic uptake of rosuvastatin.<sup>4,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Crestor (rosuvastatin). Wilmington, DE: AstraZeneca Pharmaceuticals LP, February 2012.</p>\n<p>2. Product monograph. Crestor (rosuvastatin). Mississauga, Ontario, Canada: AstraZeneca Canada Inc., October 2010.</p>\n<p>3. Simonson SG, Raza A, Martin PD, et al, “Rosuvastatin Pharmacokinetics in Heart Transplant Recipients Administered an Antirejection Regimen Including Cyclosporine,” <i>Clin Pharmacol Ther</i>, 2004, 76(2):167-77. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15289793\">[PubMed 15289793]</a></p>\n<p>4. Bergman E, Lundahl A, Fridblom P, et al, “Enterohepatic Disposition of Rosuvastatin in Pigs and the Impact of Concomitant Dosing with Cyclosporine and Gemfibrozil,” <i>Drug Metab Dispos</i>, 2009, 37(12):2349-58. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19773540\">[PubMed 19773540]</a></p>\n<p>5. Amundsen R, Christensen H, Zabihyan B, et al, “Cyclosporine A, but Not Tacrolimus, Shows Relevant Inhibition of Organic Anion-Transporting Protein 1B1-Mediated Transport of Atorvastatin,” <i>Drug Metab Dispos</i>, 2010, 38(9):1499-504. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20519340\">[PubMed 20519340]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6725":"<p><b>Title</b> Simvastatin / CycloSPORINE (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CycloSPORINE (Systemic) may increase the serum concentration of Simvastatin. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Concurrent use of simvastatin with cyclosporine is contraindicated. Consider changing to a statin that is less sensitive to this interaction (e.g., pravastatin or fluvastatin) or to an alternative type of LDL-lowering medication.</p> \n<p><b>Discussion</b> According to the simvastatin prescribing information, concurrent use with cyclosporine should be avoided.<sup>1</sup> Several published case reports describe myopathy or rhabdomyolysis in patients who received this combination.<sup>2,3,4,5,6</sup> The clearance of simvastatin was reduced in one study of 20 heart transplant patients receiving concurrent cyclosporine.<sup>7</sup> In another study of 19 post-renal transplant patients being treated with cyclosporine and simvastatin (5-10 mg/day x 6 months), the AUC of simvastatin was increased by an average of approximately 8-fold.<sup>8</sup><br><br>In contrast, several studies have described safe co-administration of simvastatin (at lower doses, generally 5-20 mg/day) and cyclosporine,<sup>9,10,11</sup> though in one of these studies, 2/26 patients did report mild myotoxicity with the combination.<sup>9</sup><br><br>This interaction is likely the result of both cyclosporine inhibition of the CYP3A-mediated metabolism of simvastatin and cyclosporine inhibition of the OATP1B1/SLCO1B1-mediated hepatic uptake of simvastatin.<sup>12</sup><br><br>One study examining the impact of simvastatin on cyclosporine concentrations reported an average 30% decrease in cyclosporine concentrations, a 29% increase in the non-protein-bound fraction of cyclosporine, and an increased cyclosporine clearance.<sup>13</sup> The clinical significance of this finding is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Zocor (simvastatin). Whitehouse Station, NJ: Merck &amp; Co., Inc., 02/2012.</p>\n<p>2. Yang WH, Zeng ZS, Ren XW, et al, “Simvastatin-induced myopathy with concomitant use of cyclosporine: case report,” <i>Int J Clin Pharmacol Ther</i>, 2011, 49(12):772-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22122820\">[PubMed 22122820]</a></p>\n<p>3. Lasocki A, Vote B, Fassett R, et al, “Simvastatin-induced rhabdomyolysis following cyclosporine treatment for uveitis,” <i>Ocul Immunol Inflamm</i>, 2007, 15(4):345-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17763133\">[PubMed 17763133]</a></p>\n<p>4. Tong J, Laport G, Lowsky R, “Rhabdomyolysis after concomitant use of cyclosporine and simvastatin in a patient transplanted for multiple myeloma,” <i>Bone Marrow Transplant</i>, 2005, 36(8):739-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16086041\">[PubMed 16086041]</a></p>\n<p>5. Gumprecht J, Zychma M, Grzeszczak W, et al, “Simvastatin-induced rhabdomyolysis in a CsA-treated renal transplant recipient,” <i>Med Sci Monit</i>, 2003, 9(9):CS89-91. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12960932\">[PubMed 12960932]</a></p>\n<p>6. Hong R, Sequeira W, “Rhabdomyolysis in a patient taking simvastatin after addition of cyclosporine therapy,” <i>J Clin Rheumatol</i>, 2000, 6(6):324-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19078494\">[PubMed 19078494]</a></p>\n<p>7. Campana C, Iacona I, Regazzi MB, et al, “Efficacy and Pharmacokinetics of Simvastatin in Heart Transplant Recipients,” <i>Ann Pharmacother</i>, 1995, 29(3):235-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7606066\">[PubMed 7606066]</a></p>\n<p>8. Ichimaru N, Takahara S, Kokado Y, et al, “Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus,” <i>Atherosclerosis</i>, 2001, 158(2):417-23. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11583721\">[PubMed 11583721]</a></p>\n<p>9. Vanhaecke J, Van Cleemput J, Van Lierde J, et al, “Safety and efficacy of low dose simvastatin in cardiac transplant recipients treated with cyclosporine,” <i>Transplantation</i>, 1994, 58(1):42-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8036706\">[PubMed 8036706]</a></p>\n<p>10. Imamura R, Ichimaru N, Moriyama T, et al, “Long term efficacy of simvastatin in renal transplant recipients treated with cyclosporine or tacrolimus,” <i>Clin Transplant</i>, 2005, 19(5):616-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16146552\">[PubMed 16146552]</a></p>\n<p>11. Arnadottir M, Eriksson LO, Germershausen JI, et al, “Low-dose simvastatin is a well-tolerated and efficacious cholesterol-lowering agent in ciclosporin-treated kidney transplant recipients: double-blind, randomized, placebo-controlled study in 40 patients,” <i>Nephron</i>, 1994, 68(1):57-62. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7991041\">[PubMed 7991041]</a></p>\n<p>12. Amundsen R, Christensen H, Zabihyan B, et al, “Cyclosporine A, but Not Tacrolimus, Shows Relevant Inhibition of Organic Anion-Transporting Protein 1B1-Mediated Transport of Atorvastatin,” <i>Drug Metab Dispos</i>, 2010, 38(9):1499-504. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20519340\">[PubMed 20519340]</a></p>\n<p>13. Akhlaghi F, McLachlan AJ, Keogh AM, et al, “Effect of simvastatin on cyclosporine unbound fraction and apparent blood clearance in heart transplant recipients,” <i>Br J Clin Pharmacol</i>, 1997, 44(6):537-42. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9431828\">[PubMed 9431828]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6726":"<p><b>Title</b> Warfarin / TraZODone</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> TraZODone may diminish the anticoagulant effect of Warfarin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Multiple reported cases, but no apparent mechanism or confirmatory studies </p> \n<p><b>Patient Management</b> Monitor clinical response to warfarin closely (i.e., INR, signs/symptoms of bleeding, etc.) when used together with trazodone. In particular, monitor for changes in response with starting/stopping trazodone or following a significant change in trazodone dose.</p> \n<p><b>Discussion</b> One case report describes a 40-year-old woman who had been stable on warfarin and had experienced a 30% decrease in her prothrombin time (PT) approximately 5 weeks after starting trazodone (titrated up to 300 mg/day).<sup>1</sup> Following an increase (by 17%) in her warfarin dose, her PT returned to normal, but after later discontinuation of the trazodone, she required a decrease in warfarin dose. Another report that resulted from a survey of medical records searching for INR changes of 1.0 or greater associated with the initiation or discontinuation of trazodone describes three similar cases.<sup>2</sup> In two cases the patients' PT/INR decreased following the initiation of trazodone, and in the other, the patient's PT/INR increased following the discontinuation of trazodone.<br><br>In contrast to these cases, another case report describes a warfarin-treated patient who experienced an increase in INR within 2 weeks of starting both trazodone and fish oil.<sup>3</sup> The inclusion of fish oil in this case is a considerable complication in the interpretation of this observed interaction, as fish oil has also been reported to potentially interact with warfarin (resulting in an increased INR).<br><br>The specific mechanism(s) for any interaction between trazodone and warfarin is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Hardy JL, Sirois A, “Reduction of Prothrombin and Partial Thromboplastin Times with Trazodone,” <i>CMAJ</i>, 1986, 135(12):1372. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3779574\">[PubMed 3779574]</a></p>\n<p>2. Small NL, Giamonna KA, “Interaction Between Warfarin and Trazodone,” <i>Ann Pharmacother</i>, 2000, 34(6):734-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10860134\">[PubMed 10860134]</a></p>\n<p>3. Jalili M, Dehpour AR, “Extremely Prolonged INR Associated with Warfarin in Combination with Both Trazodone and Omega-3 Fatty Acids,” <i>Arch Med Res</i>, 2007, 38(8):901-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17923275\">[PubMed 17923275]</a></p>\n<p>4. Buckley MS, Goff AD, Knapp WE, “Fish Oil Interaction with Warfarin,” <i>Ann Pharmacother</i>, 2004, 38(1):50-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14742793\">[PubMed 14742793]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6727":"<p><b>Title</b> DOPamine / Hyaluronidase</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Indication</b>: Avoid the use of hyaluronidase to enhance dispersion or absorption of dopamine. Use of hyaluronidase for other purposes in patients receiving dopamine may be considered as clinically indicated.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Hyaluronidase may enhance the adverse/toxic effect of DOPamine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the use of hyaluronidase to enhance dispersion or absorption of dopamine. Use of hyaluronidase for other purposes in patients receiving dopamine may be considered as clinically indicated.</p> \n<p><b>Discussion</b> The hyaluronidase prescribing information cautions that hyaluronidase should not be used to increase the rate of dopamine or alpha-agonist dispersion or absorption.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Hylenex (hyaluronidase). San Diego, CA: Halozyme Therapeutics, Inc., August 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6728":"<p><b>Title</b> Alpha-/Beta-Agonists / Hyaluronidase</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Indication</b>: Avoid the use of hyaluronidase to enhance dispersion or absorption of alpha-/beta-agonists. Use of hyaluronidase for other purposes in patients receiving alpha-/beta-agonists may be considered as clinically indicated.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Hyaluronidase may enhance the vasoconstricting effect of Alpha-/Beta-Agonists. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the use of hyaluronidase to enhance dispersion or absorption of alpha-/beta-agonists. Use of hyaluronidase for other purposes in patients receiving alpha-/beta-agonists may be considered as clinically indicated.</p>\n<div>\n <p><b>Alpha-/Beta-Agonists Interacting Members</b> Amezinium, DOPamine, Ephedra, EPHEDrine (Nasal), EPHEDrine (Systemic), EPINEPHrine (Systemic), Levonordefrin, Metaraminol, Norepinephrine<br><b>Exceptions</b> EPINEPHrine (Nasal), EPINEPHrine (Oral Inhalation), Isometheptene, Pseudoephedrine</p>\n</div> \n<p><b>Discussion</b> The hyaluronidase prescribing information cautions that hyaluronidase should not be used to increase the rate of dopamine or alpha-agonist dispersion or absorption.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Hylenex (hyaluronidase). San Diego, CA: Halozyme Therapeutics, Inc., August 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6729":"<p><b>Title</b> Phenylephrine (Systemic) / Hyaluronidase</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Indication</b>: Avoid the use of hyaluronidase to enhance dispersion or absorption of phenylephrine. Use of hyaluronidase for other purposes in patients receiving phenylephrine may be considered as clinically indicated.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Hyaluronidase may enhance the vasoconstricting effect of Phenylephrine (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the use of hyaluronidase to enhance dispersion or absorption of phenylephrine. Use of hyaluronidase for other purposes in patients receiving phenylephrine may be considered as clinically indicated.</p> \n<p><b>Discussion</b> The hyaluronidase prescribing information cautions that hyaluronidase should not be used to increase the rate of dopamine or alpha-agonist dispersion or absorption.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Hylenex (hyaluronidase). San Diego, CA: Halozyme Therapeutics, Inc., August 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6730":"<p><b>Title</b> Hyaluronidase / Corticosteroids</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Corticosteroids may diminish the therapeutic effect of Hyaluronidase. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase. Larger doses of hyaluronidase may be required.</p>\n<div>\n <p><b>Corticosteroids Interacting Members</b> Alclometasone, Amcinonide, Beclomethasone (Oral Inhalation), Beclomethasone (Topical), Betamethasone (Nasal), Betamethasone (Ophthalmic), Betamethasone (Systemic), Betamethasone (Topical), Budesonide (Oral Inhalation), Budesonide (Systemic), Budesonide (Topical), Ciclesonide (Oral Inhalation), Clobetasol, Clobetasone, Clocortolone, Corticotropin, Cortisone, Deflazacort, Desoximetasone, Dexamethasone (Systemic), Diflorasone, Diflucortolone, Fludrocortisone, Flunisolide (Oral Inhalation), Fluocinolone (Topical), Fluocinonide, Fluorometholone, Flurandrenolide, Fluticasone (Oral Inhalation), Fluticasone (Topical), Halcinonide, Halobetasol, Hydrocortisone (Systemic), Hydrocortisone (Topical), Medrysone, MethylPREDNISolone, Mometasone (Oral Inhalation), Mometasone (Topical), Prednicarbate, PrednisoLONE (Systemic), PrednisoLONE (Topical), PredniSONE, Rimexolone, Tixocortol Pivalate, Triamcinolone (Systemic), Triamcinolone (Topical)<br><b>Exceptions</b> Beclomethasone (Nasal), Budesonide (Nasal), Ciclesonide (Nasal), Desonide, Dexamethasone (Ophthalmic), Difluprednate, Flunisolide (Nasal), Fluocinolone (Ophthalmic), Fluticasone (Nasal), Hydrocortisone (Ophthalmic), Loteprednol, Mometasone (Nasal), PrednisoLONE (Ophthalmic), Triamcinolone (Nasal), Triamcinolone (Ophthalmic)</p>\n</div> \n<p><b>Discussion</b> According to the hyaluronidase prescribing information, patients receiving large doses of corticosteroids, estrogen, antihistamines, or salicylates may experience a diminished response to standard doses of hyaluronidase.<sup>1</sup> Larger hyaluronidase doses may be required to achieve the desired dispersion effect.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Hylenex (hyaluronidase). San Diego, CA: Halozyme Therapeutics, Inc., August 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6731":"<p><b>Title</b> Hyaluronidase / Salicylates</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Salicylates may diminish the therapeutic effect of Hyaluronidase. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Patients receiving salicylates (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase. Larger doses of hyaluronidase may be required.</p>\n<div>\n <p><b>Salicylates Interacting Members</b> Aminosalicylic Acid, Aspirin, Bismuth Subsalicylate, Choline Magnesium Trisalicylate, Choline Salicylate, Magnesium Salicylate, Salsalate, Sodium Salicylate, Triflusal</p>\n</div> \n<p><b>Discussion</b> According to the hyaluronidase prescribing information, patients receiving large doses of corticosteroids, estrogen, antihistamines, or salicylates may experience a diminished response to standard doses of hyaluronidase.<sup>1</sup> Larger hyaluronidase doses may be required to achieve the desired dispersion effect.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Hylenex (hyaluronidase). San Diego, CA: Halozyme Therapeutics, Inc., August 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6732":"<p><b>Title</b> Hyaluronidase / Estrogen Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Estrogen Derivatives may diminish the therapeutic effect of Hyaluronidase. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Patients receiving estrogens (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase. Larger doses of hyaluronidase may be required.</p>\n<div>\n <p><b>Estrogen Derivatives Interacting Members</b> Diethylstilbestrol, Estradiol (Systemic), Estradiol (Topical), Estriol (Systemic), Estriol (Topical), Estrogens (Conjugated A/Synthetic), Estrogens (Conjugated B/Synthetic), Estrogens (Conjugated/Equine, Systemic), Estrogens (Conjugated/Equine, Topical), Estrogens (Esterified), Estrone, Estropipate, Ethinyl Estradiol, Mestranol, Polyestradiol, Tibolone</p>\n</div> \n<p><b>Discussion</b> According to the hyaluronidase prescribing information, patients receiving large doses of corticosteroids, estrogen, antihistamines, or salicylates may experience a diminished response to standard doses of hyaluronidase.<sup>1</sup> Larger hyaluronidase doses may be required to achieve the desired dispersion effect.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Hylenex (hyaluronidase). San Diego, CA: Halozyme Therapeutics, Inc., August 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6733":"<p><b>Title</b> Hyaluronidase / Antihistamines</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antihistamines may diminish the therapeutic effect of Hyaluronidase. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase. Larger doses of hyaluronidase may be required.</p>\n<div>\n <p><b>Antihistamines Interacting Members</b> Acrivastine, Bilastine, Brompheniramine, Buclizine, Carbinoxamine, Cetirizine (Systemic), Chlorpheniramine, Clemastine, Cyclizine, Cyproheptadine, Desloratadine, Dexbrompheniramine, Dexchlorpheniramine, DimenhyDRINATE, Dimethindene (Systemic), DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Doxylamine, Ebastine, Emedastine (Systemic), Fexofenadine, HydrOXYzine, Ketotifen (Systemic), Levocetirizine, Loratadine, Meclizine, Mequitazine, Olopatadine (Systemic), Oxatomide, Oxomemazine, Pheniramine, Phenyltoloxamine, Pizotifen, Pyrilamine (Systemic), Rupatadine, Thonzylamine, Trimeprazine, Triprolidine</p>\n</div> \n<p><b>Discussion</b> According to the hyaluronidase prescribing information, patients receiving large doses of corticosteroids, estrogen, antihistamines, or salicylates may experience a diminished response to standard doses of hyaluronidase.<sup>1</sup> Larger hyaluronidase doses may be required to achieve the desired dispersion effect.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Hylenex (hyaluronidase). San Diego, CA: Halozyme Therapeutics, Inc., August 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6734":"<p><b>Title</b> Local Anesthetics / Hyaluronidase</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Hyaluronidase may enhance the adverse/toxic effect of Local Anesthetics. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Use caution when considering concurrent use of hyaluronidase with a local anesthetic. The use of such a combination may speed the onset of anesthetic action, shorten the duration of activity, and increase the risk for systemic anesthetic toxicities. Patients using such a combination should be monitored closely for evidence of systemic anesthetic toxicity.</p>\n<div>\n <p><b>Local Anesthetics Interacting Members</b> Articaine, Benoxinate, Bupivacaine, Bupivacaine (Liposomal), Chloroprocaine, Levobupivacaine, Lidocaine (Systemic), Mepivacaine, Prilocaine, Procaine, Ropivacaine, Tetracaine (Systemic)<br><b>Exceptions</b> Benzocaine, Benzydamine, Cocaine (Topical), Dibucaine, Dyclonine, Ethyl Chloride, Hexylresorcinol, Lidocaine (Ophthalmic), Lidocaine (Topical), Pramoxine, Proparacaine, Tetracaine (Ophthalmic), Tetracaine (Topical)</p>\n</div> \n<p><b>Discussion</b> The hyaluronidase prescribing information cautions that the addition of hyaluronidase to a local anesthetic may increase the speed of anesthetic action onset and reduce the swelling associated with administration but may also increase the risk for systemic absorption, resulting in a shorter duration of activity and increased toxicity of the anesthetic.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Hylenex (hyaluronidase). San Diego, CA: Halozyme Therapeutics, Inc., August 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6736":"<p><b>Title</b> Anticoagulants / Dabigatran Etexilate</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Dabigatran Etexilate may enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of dabigatran etexilate with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The combined use of dabigatran with other anticoagulants should be avoided under most circumstances. Some limited combined use with warfarin may be indicated during periods of transition from dabigatran to warfarin. See the full Lexi-Drugs monograph for specific recommendations on switching anticoagulant treatment to or from dabigatran. Canadian product labeling lists concomitant use of dabigatran with other anticoagulants as contraindicated.</p>\n<div>\n <p><b>Anticoagulants Interacting Members</b> Antithrombin, Apixaban, Argatroban, Bemiparin, Betrixaban, Bivalirudin, Dabigatran Etexilate, Dalteparin, Danaparoid, Desirudin, Edoxaban, Enoxaparin, Fondaparinux, Heparin, Nadroparin, Phenindione, Protein C Concentrate (Human), Rivaroxaban, Tinzaparin<br><b>Exceptions</b> Acenocoumarol, Warfarin</p>\n</div> \n<p><b>Discussion</b> The use of dabigatran in combination with other anticoagulants is expected to increase the risk of bleeding, and should generally be avoided.<sup>1,2</sup> Some limited combined use with warfarin may be indicated during periods of transition from dabigatran to warfarin treatment.<sup>1,2</sup> See the full drug monograph for specific recommendations on switching anticoagulant treatment to or from dabigatran.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Product monograph. Pradax (dabigatran etexilate). Burlington, Ontario, Canada: Boehringer Ingelheim Canada Ltd., January 2012.</p>\n<p>2. Prescribing information. Pradaxa (dabigatran etexilate). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., November 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6738":"<p><b>Title</b> Dabigatran Etexilate / Agents with Antiplatelet Properties</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Indication</b>: Specific recommendations for management of this interaction may be different for those receiving aspirin for stroke prevention in atrial fibrillation vs. those receiving aspirin for other indications.</p></li>\n <li><p><b>International labeling</b>: Recommendations in the Canadian labeling regarding the management of this interaction are somewhat different from those in the U.S. labeling. Canadian labeling also states that concomitant use of prasugrel or ticagrelor is not recommended. Additionally, UK labeling lists the use of intravenous diclofenac in combination with anticoagulants as contraindicated.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Carefully consider the anticipated risks and benefits of this combination. Increase monitoring for evidence of bleeding if dabigatran is used in combination with any antiplatelet agent. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use of prasugrel or ticagrelor, and it additionally recommends that low dose (100 mg/day) aspirin could be considered if necessary but that use of antithrombotics is not recommended for stroke prevention in patients with atrial fibrillation.</p>\n<div>\n <p><b>Agents with Antiplatelet Properties Interacting Members</b> Abciximab, Aceclofenac, Acemetacin, Anagrelide, Aspirin, Cangrelor, Cilostazol, Citalopram, Clopidogrel, Dapoxetine, Defibrotide, Desvenlafaxine, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dilazep, Dipyridamole, Dipyrone, DULoxetine, Eptifibatide, Escitalopram, Etodolac, Etofenamate, Fenoprofen, Floctafenine, FLUoxetine, Flurbiprofen (Systemic), FluvoxaMINE, Ibuprofen, Ibuprofen (Topical), Indobufen, Indomethacin, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Levomilnacipran, Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Milnacipran, Nabumetone, Naproxen, Oxaprozin, PARoxetine, Pelubiprofen, Phenylbutazone, Piracetam, Piroxicam (Systemic), Piroxicam (Topical), Prasugrel, Propyphenazone, Sarpogrelate, Sertraline, Sulfinpyrazone, Sulindac, Tenoxicam, Tiaprofenic Acid, Ticagrelor, Ticlopidine, Tirofiban, Tolfenamic Acid, Tolmetin, Triflusal, Venlafaxine, Vilazodone, Vorapaxar, Vortioxetine, Zaltoprofen</p>\n</div> \n<p><b>Discussion</b> The use of dabigatran in combination with any antiplatelet agent is expected to increase the risk of bleeding. In patients with atrial fibrillation treated with aspirin or clopidogrel for prevention of stroke and systemic embolism, the risk of major bleeding with dabigatran was approximately doubled, without any apparent benefit in reducing embolic risk.<sup>1</sup> The dabigatran Canadian product monograph recommends avoiding concomitant use of dabigatran with prasugrel or ticagrelor, apparently due to a lack of studies with such combinations.<sup>1</sup> It additionally recommends that low dose (100 mg/day) aspirin could be considered if medically necessary, but should not be used for stroke prevention in patients with atrial fibrillation. U.S. prescribing information for dabigatran does not recommend any specific antiplatelet agents that should be avoided, or additional action that should be taken to limit bleeding risk with these combinations.<sup>2</sup><br><br>In addition to the expected pharmacodynamic interaction between dabigatran and antiplatelet agents, clopidogrel specifically increased dabigatran maximum concentration and AUC by 30% and 40%, respectively.<sup>1</sup> The mechanism of this interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Pradaxa (dabigatran etexilate) [product monograph]. Burlington, Ontario, Canada: Boehringer Ingelheim Canada Ltd.; June 2015.</p>\n<p>2. Pradaxa (dabigatran etexilate) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; January 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6739":"<p><b>Title</b> Dabigatran Etexilate / Thrombolytic Agents</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Indication</b>: Consider avoiding alteplase treatment of acute ischemic stroke in patients receiving dabigatran. See full drug monograph for details.</p></li>\n <li><p><b>International labeling</b>: Recommendations in the Canadian labeling regarding the management of this interaction are somewhat different from those in the U.S. labeling.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Thrombolytic Agents may enhance the anticoagulant effect of Dabigatran Etexilate. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Carefully monitor for signs and symptoms of bleeding when using dabigatran in combination with any thrombolytic agent. The Canadian product monograph for dabigatran specifically recommends avoiding such a combination. Consider avoiding alteplase treatment of acute ischemic stroke in patients receiving dabigatran (see full drug monograph for details).</p>\n<div>\n <p><b>Thrombolytic Agents Interacting Members</b> Alteplase, Defibrotide, Reteplase, Streptokinase, Tenecteplase, Urokinase</p>\n</div> \n<p><b>Discussion</b> The use of dabigatran in combination with any thrombolytic agent is expected to increase the risk of bleeding. The dabigatran Canadian product monograph recommends avoiding concomitant use of dabigatran with such agents,<sup>1</sup> while U.S. prescribing information gives no specific recommendation.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Product monograph. Pradax (dabigatran etexilate). Burlington, Ontario, Canada: Boehringer Ingelheim Canada Ltd., January 2012.</p>\n<p>2. Prescribing information. Pradaxa (dabigatran etexilate). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., November 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6740":"<p><b>Title</b> Antiarrhythmic Agents (Class Ia) / Propafenone</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Propafenone may enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class Ia). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of propafenone with quinidine, amiodarone, or other class IA or class III antiarrhythmics should be avoided. Treatment with such agents should be withheld for at least 5 half-lives prior to initiation of propafenone.</p>\n<div>\n <p><b>Antiarrhythmic Agents (Class Ia) Interacting Members</b> Ajmaline, Disopyramide, Procainamide, QuiNIDine</p>\n</div> \n<p><b>Discussion</b> No case reports or study data describe significant QT interval prolongation with combined use of propafenone with any QT-prolonging drugs. Similarly, the propafenone prescribing information recommends avoiding concurrent use with class IA (e.g., quinidine) or class III antiarrhythmics (e.g., amiodarone), and cautions that concurrent use with other such QT-prolonging drugs is not well-studied.<sup>1</sup><br><br>Despite one case report describing a patient who had previously experienced Torsade de Pointes (TdP) while being treated with quinidine and later experienced another occurrence of TdP while being treated with propafenone (after having the initial TdP resolve and having previously discontinued quinidine).<sup>2</sup> Another report described several patients who experienced malignant ventricular arrhythmias during treatment with propafenone, though these episodes were not associated with any QT interval prolongation.<sup>3</sup><br><br>Several studies that have examined the impact of propafenone on the QT interval in both patients with heart disease and in those free of any structural heart disease have concluded that propafenone does not significantly effect the QT interval or most other measures of ventricular repolarization.<sup>4,5,6</sup> One study did, however, report that propafenone did increase QT interval dispersion, which is a potential marker of increased proarrhythmia risk.<sup>4</sup> The propafenone prescribing information states that propafenone may increase the QT interval but that its prolongation of the QRS duration makes any QT effects difficult to interpret.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Rythmol SR (propafenone). Research Triangle Park, NC: GlaxoSmithKline, February 2013.</p>\n<p>2. Hii JT, Wyse DG, Gillis AM, et al, “Propafenone-Induced Torsade de Pointes: Cross-Reactivity with Quinidine,” <i>Pacing Clin Electrophysiol</i>, 1991, 14(11 Pt 1):1568-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1721143\">[PubMed 1721143]</a></p>\n<p>3. Buss J, Neuss H, Bilgin Y, et al, “Malignant Ventricular Tachyarrhythmias in Association with Propafenone Treatment,” <i>Eur Heart J</i>, 1985, 6(5):424-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4043097\">[PubMed 4043097]</a></p>\n<p>4. Puljevic D, Smalcelj A, Durakovic Z, et al, “The Influence of Atenolol and Propafenone on QT Interval Dispersion in Patients 3 Months After Myocardial Infarction,” <i>Int J Clin Pharmacol Ther</i>, 1997, 35(9):381-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9314091\">[PubMed 9314091]</a></p>\n<p>5. Sarubbi B, Ducceschi V, Briglia N, et al, “Compared Effects of Sotalol, Flecainide and Propafenone on Ventricular Repolarization in Patients Free of Underlying Structural Heart Disease,” <i>Int J Cardiol</i>, 1998, 66(2):157-64. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9829329\">[PubMed 9829329]</a></p>\n<p>6. Napoli C, Sorice P, Di Benedetto A, et al, “Propafenone in the Conversion of Atrial Fibrillation in Patients Suffering from Chronic Renal Failure,” <i>Am J Ther</i>, 1997, 4(4):130-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10423602\">[PubMed 10423602]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6741":"<p><b>Title</b> Antiarrhythmic Agents (Class III) / Propafenone</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Propafenone may enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class III). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of propafenone with quinidine, amiodarone, or other class IA or class III antiarrhythmics should be avoided. Treatment with such agents should be withheld for at least 5 half-lives prior to initiation of propafenone.</p>\n<div>\n <p><b>Antiarrhythmic Agents (Class III) Interacting Members</b> Amiodarone, Dofetilide, Dronedarone, Ibutilide, Sotalol, Vernakalant</p>\n</div> \n<p><b>Discussion</b> No case reports or study data describe significant QT interval prolongation with combined use of propafenone with any QT-prolonging drugs. Similarly, the propafenone prescribing information recommends avoiding concurrent use with class IA (e.g., quinidine) or class III antiarrhythmics (e.g., amiodarone), and cautions that concurrent use with other such QT-prolonging drugs is not well-studied.<sup>1</sup><br><br>Despite one case report describing a patient who had previously experienced Torsade de Pointes (TdP) while being treated with quinidine and later experienced another occurrence of TdP while being treated with propafenone (after having the initial TdP resolve and having previously discontinued quinidine).<sup>2</sup> Another report described several patients who experienced malignant ventricular arrhythmias during treatment with propafenone, though these episodes were not associated with any QT interval prolongation.<sup>3</sup><br><br>Several studies that have examined the impact of propafenone on the QT interval in both patients with heart disease and in those free of any structural heart disease have concluded that propafenone does not significantly effect the QT interval or most other measures of ventricular repolarization.<sup>4,5,6</sup> One study did, however, report that propafenone did increase QT interval dispersion, which is a potential marker of increased proarrhythmia risk.<sup>4</sup> The propafenone prescribing information states that propafenone may increase the QT interval but that its prolongation of the QRS duration makes any QT effects difficult to interpret.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Rythmol SR (propafenone). Research Triangle Park, NC: GlaxoSmithKline, February 2013.</p>\n<p>2. Hii JT, Wyse DG, Gillis AM, et al, “Propafenone-Induced Torsade de Pointes: Cross-Reactivity with Quinidine,” <i>Pacing Clin Electrophysiol</i>, 1991, 14(11 Pt 1):1568-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1721143\">[PubMed 1721143]</a></p>\n<p>3. Buss J, Neuss H, Bilgin Y, et al, “Malignant Ventricular Tachyarrhythmias in Association with Propafenone Treatment,” <i>Eur Heart J</i>, 1985, 6(5):424-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4043097\">[PubMed 4043097]</a></p>\n<p>4. Puljevic D, Smalcelj A, Durakovic Z, et al, “The Influence of Atenolol and Propafenone on QT Interval Dispersion in Patients 3 Months After Myocardial Infarction,” <i>Int J Clin Pharmacol Ther</i>, 1997, 35(9):381-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9314091\">[PubMed 9314091]</a></p>\n<p>5. Sarubbi B, Ducceschi V, Briglia N, et al, “Compared Effects of Sotalol, Flecainide and Propafenone on Ventricular Repolarization in Patients Free of Underlying Structural Heart Disease,” <i>Int J Cardiol</i>, 1998, 66(2):157-64. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9829329\">[PubMed 9829329]</a></p>\n<p>6. Napoli C, Sorice P, Di Benedetto A, et al, “Propafenone in the Conversion of Atrial Fibrillation in Patients Suffering from Chronic Renal Failure,” <i>Am J Ther</i>, 1997, 4(4):130-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10423602\">[PubMed 10423602]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6744":"<p><b>Title</b> Dabigatran Etexilate / Sulfinpyrazone</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Sulfinpyrazone may enhance the anticoagulant effect of Dabigatran Etexilate. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Canadian product labeling for dabigatran specifically recommends avoiding concomitant use of dabigatran and sulfinpyrazone.</p> \n<p><b>Discussion</b> The dabigatran Canadian product monograph recommends avoiding concomitant use of sulfinpyrazone.<sup>1</sup> No clinical data characterizing the magnitude and significance of this interaction are available, but the use of dabigatran in combination with any antiplatelet agent is expected to increase the risk of bleeding.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Product monograph. Pradax (dabigatran etexilate). Burlington, Ontario, Canada: Boehringer Ingelheim Canada Ltd., January 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6745":"<p><b>Title</b> Repaglinide / Deferasirox</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Deferasirox may increase the serum concentration of Repaglinide. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor clinical response (serum glucose, signs/symptoms of hypoglycemia, etc.) to repaglinide closely when used with deferasirox.</p> \n<p><b>Discussion</b> The repaglinide AUC and maximum serum concentration (Cmax) were an average of 2.3-fold and 62% higher, respectively, when repaglinide (0.5 mg, single dose) was given with deferasirox (30 mg/kg/day x 4 days) in a study of 24 healthy volunteers.<sup>1</sup> The increased repaglinide concentrations were associated with only a moderately increased glucose-lowering effect among the healthy volunteers in the study. Repaglinide is a substrate for both CYP2C8 and CYP3A4,<sup>2</sup> and deferasirox is a weak-to-moderate inhibitor of CYP2C8.<sup>1,3</sup> Due to the results of this study, deferasirox prescribing information recommends close monitoring of repaglinide response, consideration of using a lower repaglinide dose, and caution with all CYP2C8 substrates.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Skerjanec A, Wang J, Maren K, et al, “Investigation of the Pharmacokinetic Interactions of Deferasirox, a Once-Daily Oral Iron Chelator, with Midazolam, Rifampin, and Repaglinide in Healthy Volunteers,” <i>J Clin Pharmacol</i>, 2010, 50(2):205-13. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19940232\">[PubMed 19940232]</a></p>\n<p>2. Prescribing information. Prandin (repaglinide). Princeton, NJ: Novo Nordisk Inc., March 2012.</p>\n<p>3. Prescribing information. Exjade (deferasirox). East Hanover, NJ: Novartis Pharmaceuticals Corporation, April 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6746":"<p><b>Title</b> Sulfonylureas / Probenecid</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Probenecid may decrease the protein binding of Sulfonylureas. Probenecid may increase the serum concentration of Sulfonylureas. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for enhanced sulfonylurea pharmacologic effects (e.g., hypoglycemia) in patients receiving concomitant probenecid.</p>\n<div>\n <p><b>Sulfonylureas Interacting Members</b> ChlorproPAMIDE, Gliclazide, Glimepiride, GlipiZIDE, GlyBURIDE, TOLAZamide, TOLBUTamide</p>\n</div> \n<p><b>Discussion</b> Probenecid U.S. prescribing information cautions that the pharmacologic action of oral sulfonylreas may be enhanced and/or prolonged by probenecid.<sup>1</sup> Probenecid may competitvely inhibit the renal tubular excretion of sulfonylureas. Another proposed mechanism includes the displacement of sulfonylureas from their plasma protein binding sites by probenecid.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Probenecid. Morgantown, WV: Mylan Pharmaceuticals Inc., March 2006.</p>\n<p>2. Prescribing information. Glimepiride (Amaryl). Bridgewater, NJ: Sanofi-Aventis U.S. LLC, May 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6747":"<p><b>Title</b> ARIPiprazole / PARoxetine</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b> (CYP3A4 Inhibitors): Further aripiprazole dose reductions may be recommended with concomitant use of a CYP3A4 inhibitor.</p></li>\n <li><p><b>Indication</b>: Aripiprazole dose reduction is not recommended when used as adjunctive therapy for major depressive disorder.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> PARoxetine may enhance the adverse/toxic effect of ARIPiprazole. Specifically, the risk of neuroleptic malignant syndrome may be increased. ARIPiprazole may enhance the serotonergic effect of PARoxetine. This could result in serotonin syndrome. PARoxetine may increase the serum concentration of ARIPiprazole. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> <u>For aripiprazole formulations other than the extended-release injectable</u>: decrease the aripiprazole dose to 50% of the usual dose when initiating concomitant therapy with any strong CYP2D6 inhibitor (e.g., paroxetine, fluoxetine, quinidine), and further to 25% of the usual dose in patients who are also receiving strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole). Dose reductions up to 75% could also be considered when combining a strong CYP2D6 inhibitor with a less potent CYP3A4 inhibitor. Aripiprazole dose adjustment is not recommended when used as adjunctive therapy in patients with major depressive disorder and receiving a CYP2D6 inhibitor. <br><u>For extended-release injectable aripiprazole</u>: the following dose adjustments are recommended only when inhibitors are given for more than 14 days. In patients who would normally receive a 400 mg aripiprazole dose, reduce dose to 300 mg when given with a strong CYP2D6 inhibitor and further to 200 mg in patients who are also receiving CYP3A4 inhibitors; in patients who would normally receive a 300 mg dose, reduce dose to 200 mg when given with a strong CYP2D6 inhibitor and further to 160 mg in patients who are also receiving CYP3A4 inhibitors. Increase aripiprazole doses proportionately following discontinuation of treatment with CYP3A4 and/or CYP2D6 inhibitors.</p> \n<p><b>Discussion</b> In a clinical study of 7 healthy volunteers considered CYP2D6 extensive metabolizers (based on *1/*1 or *1/*10 genotype), coadministration of paroxetine (20 mg/day) increased the maximum concentration and AUC of aripiprazole (6 mg/day) by 1.4 and 2.4 fold, respectively.<sup>1</sup> In another study, aripiprazole (6-24 mg/day) concentrations 13 hours post dose increased by 1.7 fold following initiation of paroxetine (20 mg/day) in 14 schizophrenic patients.<sup>2</sup> Concentrations of dehydroaripiprazole were unchanged.<br><br>The likely primary mechanism of this interaction is paroxetine inhibition of CYP2D6 mediated aripiprazole metabolism. Aripiprazole prescribing information recommends dose reduction when used in combination with paroxetine, although no dose adjustment is recommended when oral aripiprazole is used adjunctively in the treatment of major depressive disorder.<sup>3,4</sup> Further aripiprazole dose reductions may be warranted when patients are treated with paroxetine in combination with an inhibitor of the other main pathway of aripiprazole elimination, CYP3A4.<br><br>In addition to the pharmacokinetic interaction between these agents, coadministration could theoretically increase the risk of serotonin toxicity and neuroleptic malignant syndrome. There are no published cases describing these effects with paroxetine, although one case of possible neuroleptic malignant syndrome and/or serotonin syndrome has been reported with the related agent fluoxetine given with aripiprazole.<sup>5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Azuma J, Hasunuma T, Kubo M, et al, “The Relationship Between Clinical Pharmacokinetics of Aripiprazole and CYP2D6 Genetic Polymorphism: Effects of CYP Enzyme Inhibition by Coadministration of Paroxetine or Fluvoxamine,” <i>Eur J Clin Pharmacol</i>, 2012, 68(1):29-37. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21739267\">[PubMed 21739267]</a></p>\n<p>2. Nemoto K, Mihara K, Nakamura A, et al, “Effects of Paroxetine on Plasma Concentrations of Aripiprazole and its Active Metabolite, Dehydroaripiprazole, in Japanese Patients With Schizophrenia,” <i>Ther Drug Monit</i>, 2012, 34(2):188-92. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22377745\">[PubMed 22377745]</a></p>\n<p>3. Prescribing information. Abilify (aripiprazole). Princeton, NJ: Bristol-Myers Squibb, February, 2012.</p>\n<p>4. Prescribing information. Abilify Maintena (aripiprazole). Rockville, MD: Otsuka America Pharmaceutical, Inc., February 2013.</p>\n<p>5. Duggal HS and Kithas J, “Possible Neuroleptic Malignant Syndrome With Aripiprazole and Fluoxetine,” <i>Am J Psychiatry</i>, 2005, 162(2):397-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15677611\">[PubMed 15677611]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6748":"<p><b>Title</b> ARIPiprazole / FLUoxetine</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b> (CYP3A4 Inhibitors): Further aripiprazole dose reductions may be recommended with concomitant use of a CYP3A4 inhibitor.</p></li>\n <li><p><b>Indication</b>: Aripiprazole dose reduction is not recommended when used as adjunctive therapy for major depressive disorder.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> FLUoxetine may enhance the adverse/toxic effect of ARIPiprazole. Specifically, the risk of neuroleptic malignant syndrome may be increased. ARIPiprazole may enhance the serotonergic effect of FLUoxetine. This could result in serotonin syndrome. FLUoxetine may increase the serum concentration of ARIPiprazole. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> <u>For aripiprazole formulations other than the extended-release injectable</u>: decrease the aripiprazole dose to 50% of the usual dose when initiating concomitant therapy with any strong CYP2D6 inhibitor (e.g., paroxetine, fluoxetine, quinidine), and further to 25% of the usual dose in patients who are also receiving strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole). Dose reductions up to 75% could also be considered when combining a strong CYP2D6 inhibitor with a less potent CYP3A4 inhibitor. Aripiprazole dose adjustment is not recommended when used as adjunctive therapy in patients with major depressive disorder and receiving a CYP2D6 inhibitor. <br><u>For extended-release injectable aripiprazole</u>: the following dose adjustments are recommended only when inhibitors are given for more than 14 days. In patients who would normally receive a 400 mg aripiprazole dose, reduce dose to 300 mg when given with a strong CYP2D6 inhibitor and further to 200 mg in patients who are also receiving CYP3A4 inhibitors; in patients who would normally receive a 300 mg dose, reduce dose to 200 mg when given with a strong CYP2D6 inhibitor and further to 160 mg in patients who are also receiving CYP3A4 inhibitors. Increase aripiprazole doses proportionately following discontinuation of treatment with CYP3A4 and/or CYP2D6 inhibitors.</p> \n<p><b>Discussion</b> Fluoxetine acts as a strong inhibitor of CYP2D6, one of the two known major pathways of aripiprazole metabolism, at clinically achieved concentrations. While no clinical data are available describing the magnitude of pharmacokinetic interaction between fluoxetine and aripiprazole, aripiprazole AUC increased by greater than 2 fold when coadministered with the strong CYP2D6 inhibitors quinidine and paroxetine in patients considered CYP2D6 extensive metabolizers.<sup>1,2</sup> Aripiprazole dose reductions may be required in patients treated with fluoxetine, particularly when used in combination with an inhibitor of the other main pathway of aripiprazole elimination, CYP3A4.<sup>1,4</sup><br><br>In addition to the pharmacokinetic interaction between these agents, coadministration could theoretically increase the risk of serotonin toxicity and neuroleptic malignant syndrome. One published case report describes possible neuroleptic malignant syndrome and/or serotonin syndrome in a patient who initiated aripiprazole (30 mg/day) and fluoxetine (20 mg/day) concurrently.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Abilify (aripiprazole). Princeton, NJ: Bristol-Myers Squibb, February, 2012.</p>\n<p>2. Azuma J, Hasunuma T, Kubo M, et al, “The Relationship Between Clinical Pharmacokinetics of Aripiprazole and CYP2D6 Genetic Polymorphism: Effects of CYP Enzyme Inhibition by Coadministration of Paroxetine or Fluvoxamine,” <i>Eur J Clin Pharmacol</i>, 2012, 68(1):29-37. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21739267\">[PubMed 21739267]</a></p>\n<p>3. Duggal HS and Kithas J, “Possible Neuroleptic Malignant Syndrome With Aripiprazole and Fluoxetine,” <i>Am J Psychiatry</i>, 2005, 162(2):397-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15677611\">[PubMed 15677611]</a></p>\n<p>4. Prescribing information. Abilify Maintena (aripiprazole). Rockville, MD: Otsuka America Pharmaceutical, Inc., February 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6749":"<p><b>Title</b> PAZOPanib / HMG-CoA Reductase Inhibitors (Statins)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> HMG-CoA Reductase Inhibitors (Statins) may enhance the hepatotoxic effect of PAZOPanib. Specifically, the risk for increased serum transaminase concentrations may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients closely for increased AST/ALT concentrations when pazopanib is used with an HMG-CoA reductase inhibitor (“statin”). The pazopanib label specifies simvastatin in this warning, citing inadequate information with other statins to determine whether the risk differs among the various statins. For patients who experience an elevated AST/ALT on this combination, consider adjusting the pazopanib dose (according to the prescribing information) or discontinuation of the statin. As atorvastatin appears to be an inhibitor of p-glycoprotein, use of atorvastatin with pazopanib should be avoided when possible.</p>\n<div>\n <p><b>HMG-CoA Reductase Inhibitors (Statins) Interacting Members</b> Fluvastatin, Lovastatin, Pitavastatin, Pravastatin, Red Yeast Rice, Rosuvastatin, Simvastatin<br><b>Exception</b> AtorvaSTATin</p>\n</div> \n<p><b>Discussion</b> According to the pazopanib prescribing information the incidence of elevated ALT concentrations was higher among patients receiving pazopanib plus simvastatin (27%, 11/41) than among patients receiving pazopanib without simvastatin (14%, 126/895).<sup>1</sup> The degree to which this apparent risk applies to other statins is unknown.<br><br>The specific mechanism for this interaction is uncertain. Both simvastatin (along with other statins) and pazopanib have some independent risk for causing elevated AST/ALT concentrations and hepatotoxicity.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Votrient (pazopanib). Research Triangle Park, NC: GlaxoSmithKline; March 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6750":"<p><b>Title</b> Zolpidem / CNS Depressants</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Brand Name</b>: A dose reduction is recommended for Intermezzo brand sublingual zolpidem (applies to men only) but is not applicable to the other zolpidem products.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CNS Depressants may enhance the CNS depressant effect of Zolpidem. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> When possible, avoid the concurrent use of zolpidem with other CNS depressants. If concurrent use can not be avoided, consider using a lower dose of the other CNS depressant when possible. The use of zolpidem with alcohol is specifically not recommended. The use of Intermezzo brand zolpidem sublingual tablets with other sedative-hypnotics at bedtime or in the middle of the night is also specifically not recommended. A reduced Intermezzo brand sublingual zolpidem adult dose of 1.75 mg is recommended for men using sublingual zolpidem who are also receiving other CNS depressants. No specific dose reduction is recommended for women using Intermezzo together with other CNS depressants. All patients using such a combination should be strongly cautioned about the potential for prolonged and/or excessive CNS depression, and such patients should be followed closely for evidence of excessive CNS depression and/or psychomotor impairment.</p>\n<div>\n <p><b>CNS Depressants Interacting Members</b> Acrivastine, Afloqualone, Alcohol (Ethyl), Alfentanil, ALPRAZolam, Amisulpride, Amitriptyline, Amobarbital, Amoxapine, ARIPiprazole, ARIPiprazole Lauroxil, Asenapine, Baclofen, Benperidol, Benzhydrocodone, Bilastine, Blonanserin, Brexpiprazole, Brimonidine (Ophthalmic), Brivaracetam, Bromazepam, Bromperidol, Brompheniramine, Buclizine, Buprenorphine, BusPIRone, Butabarbital, Butalbital, Butorphanol, CarBAMazepine, Carbinoxamine, Cariprazine, Carisoprodol, Cetirizine (Systemic), Chloral Betaine, Chloral Hydrate, ChlordiazePOXIDE, Chlormethiazole, Chlorpheniramine, ChlorproMAZINE, Chlorzoxazone, Cinnarizine, Clemastine, CloBAZam, ClomiPRAMINE, ClonazePAM, CloNIDine, Clorazepate, Clothiapine, CloZAPine, Codeine, Cyclizine, Cyclobenzaprine, Cyproheptadine, Dantrolene, Desflurane, Desipramine, Desloratadine, Deutetrabenazine, Dexbrompheniramine, Dexchlorpheniramine, DiazePAM, Difenoxin, Dihydrocodeine, DimenhyDRINATE, Dimethindene (Systemic), DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Diphenoxylate, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Efavirenz, Emedastine (Systemic), Entacapone, Eperisone, Estazolam, Eszopiclone, Ethosuximide, Ethotoin, Ethyl Loflazepate, Etizolam, Ezogabine, Felbamate, FentaNYL, Fexofenadine, Flibanserin, Flunarizine, Flunitrazepam, Flupentixol, FluPHENAZine, Flurazepam, Fosphenytoin, Gabapentin, Gabapentin Enacarbil, Glutethimide, GuanFACINE, Haloperidol, Halothane, Heroin, HYDROcodone, HYDROmorphone, HydrOXYzine, Iloperidone, Imipramine, Isoflurane, Ketamine, Ketotifen (Systemic), LamoTRIgine, LevETIRAcetam, Levocetirizine, Levorphanol, Lofepramine, Loprazolam, Loratadine, LORazepam, Lormetazepam, Loxapine, Lurasidone, Maprotiline, Meclizine, Melitracen [INT], Meperidine, Meprobamate, Meptazinol, Mequitazine, Metaxalone, Methadone, Methocarbamol, Methohexital, Methotrimeprazine, Methoxyflurane, Methsuximide, Mianserin, Midazolam, Mirtazapine, Molindone, Morphine (Liposomal), Morphine (Systemic), Moxonidine, Nalbuphine, Nalfurafine, Nefopam, Nitrazepam, Nitrous Oxide, Nordazepam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Opium, Opium Tincture, Orphenadrine, Oxatomide, Oxazepam, Oxomemazine, OxyCODONE, OxyMORphone, Paliperidone, Paraldehyde, Paregoric, Pentazocine, PENTobarbital, Perampanel, Periciazine, Perphenazine, Pheniramine, PHENobarbital, Phenyltoloxamine, Phenytoin, Pholcodine, Pimozide, Pipamperone [INT], Pipotiazine, Pizotifen, Pomalidomide, Prazepam, Pregabalin, Primidone, Prochlorperazine, Promazine, Promethazine, Propofol, Protriptyline, Pyrilamine (Systemic), Quazepam, QUEtiapine, Ramelteon, Remifentanil, Reserpine, Rilmenidine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Secobarbital, Sevoflurane, Sodium Oxybate, Stiripentol, SUFentanil, Sulpiride, Suvorexant, Tapentadol, Tasimelteon, Temazepam, Tetrabenazine, Thalidomide, Thiopental, Thioridazine, Thiothixene, Thonzylamine, TiaGABine, TiZANidine, Tofisopam, Tolcapone, Topiramate, TraMADol, Triazolam, Trifluoperazine, Trimeprazine, Trimipramine, Triprolidine, Valerian, Vigabatrin, Zaleplon, Ziconotide, Ziprasidone, Zolpidem, Zonisamide, Zopiclone, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> The prescribing information for both the sublingual and oral zolpidem tablets caution that concurrent use with other CNS depressants may result in enhanced CNS depression and may require dose adjustments of the other CNS depressant and/or zolpidem.<sup>1,2,3</sup> Further, the prescribing information for the Intermezzo brand zolpidem sublingual tablet recommends a dose reduction for men (from 3.5 mg to 1.75 mg) when used with other CNS depressants. Though all zolpidem products acknowledge that dose adjustments may be required with other CNS depressants, the Intermezzo brand product specifically recommends avoiding concurrent use of other sedative-hypnotics at bedtime or in the middle of the night.<sup>1</sup> Conversely, the prescribing information for the other zolpidem products do not specifically recommend avoiding use with CNS depressants at bedtime (other than alcohol, which is generally not recommended to be used with zolpidem).<sup>2,3</sup><br><br>Concurrent use of zolpidem with other CNS depressants has been associated with greater psychomotor impairment, next-day driving impairment, and an increased risk for complex behaviors such as “sleep driving”, etc.<sup>1,2,3</sup><br><br>The specific mechanism for this specific interaction appears to be additive or synergistic CNS depressant effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Intermezzo (zolpidem). Point Richmond, CA: Transcept Pharmaceuticals, Inc., November 2011.</p>\n<p>2. Prescribing information. Edluar (zolpidem). Somerset, NJ: Meda Pharmaceuticals Inc., 10/10.</p>\n<p>3. Prescribing information. Ambien (zolpidem). Bridgewater, NJ: sanofi-aventis U.S. LLC, August 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6751":"<p><b>Title</b> DULoxetine / ARIPiprazole</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b> (CYP3A4 Inhibitors): Aripiprazole dose reductions may be recommended with concomitant use of a CYP3A4 inhibitor.</p></li>\n <li><p><b>Genotype</b>: CYP2D6 \"poor metabolizers\" may require aripiprazole dose adjustment independent of duloxetine coadministraiton. See dosing information in the full product monograph.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> ARIPiprazole may enhance the adverse/toxic effect of DULoxetine. ARIPiprazole may enhance the serotonergic effect of DULoxetine. This could result in serotonin syndrome. DULoxetine may increase the serum concentration of ARIPiprazole. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patient response closely when aripiprazole is used with a moderate CYP2D6 inhibitor (e.g., duloxetine, erythromycin), due to potential risks of increased aripiprazole systemic exposure and effects. <u>For aripiprazole formulations other than the extended-release injectable</u>: consider reducing initial aripiprazole dose to as little as 25% of the usual dose, and titrating to the desired clinical response, in patients receiving a moderate CYP2D6 inhibitor with any CYP3A4 inhibitor (particularly strong inhibitors such as ketoconazole, itraconazole). Dose adjustment is not recommended when aripiprazole is used as adjunctive therapy in patients with major depressive disorder and receiving a CYP2D6 inhibitor. <br><u>For extended-release injectable aripiprazole</u>: the following dose adjustments are recommended only when inhibitors are given for more than 14 days. In patients who would normally receive a 400 mg aripiprazole dose, reduce dose to 200 mg when given with a CYP2D6 inhibitor in combination with a CYP3A4 inhibitor; in patients who would normally receive a 300 mg dose, reduce dose to 160 mg when given with a CYP2D6 inhibitor in combination with a CYP3A4 inhibitor. Increase aripiprazole doses proportionately following discontinuation of treatment with CYP3A4 and/or CYP2D6 inhibitors.</p> \n<p><b>Discussion</b> Duloxetine can act as a moderate inhibitor of CYP2D6 at clinically achieved concentrations, and may therefore increase aripiprazole systemic concentrations and effects. Enhanced clinical monitoring and aripiprazole dose reductions may be indicated, particularly during concomitant treatment with an inhibitor of aripiprazole's other primary route of metabolism, CYP3A4.<sup>1,2</sup> In one small retrospective review, 7 patients receiving duloxetine with aripiprazole did not have significantly greater serum concentrations of aripiprazole compared to patients who received aripiprazole alone.<sup>3</sup> <br><br>In addition to the potential pharmacokinetic interaction between these agents, coadministration could theoretically increase the risk of serotonin toxicity and neuroleptic malignant syndrome.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Abilify (aripiprazole). Princeton, NJ: Bristol-Myers Squibb, February, 2012.</p>\n<p>2. Prescribing information. Abilify Maintena (aripiprazole). Rockville, MD: Otsuka America Pharmaceutical, Inc., February 2013.</p>\n<p>3. Hendset M, Molden E, Enoksen TB, et al, “The Effect of Coadministration of Duloxetine on Steady-State Serum Concentration of Risperidone and Aripiprazole: A Study Based on Therapeutic Drug Monitoring Data,” <i>Ther Drug Monit</i>, 2010, 32(6):787-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21068650\">[PubMed 21068650]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6756":"<p><b>Title</b> Methadone / Voriconazole</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Voriconazole may increase the serum concentration of Methadone. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor clinical response to methadone closely when used with voriconazole. In particular monitor patients closely for evidence of methadone toxicities, including but not limited to respiratory depression and QT-prolongation/torsades de pointes. Methadone dose reductions may be required when used with voriconazole.</p> \n<p><b>Discussion</b> The average AUC for (R)- and (S)-methadone were increased 47% and 103%, respectively, when voriconazole (400 mg every 12 hours x 1 day, then 200 mg every 12 hours x 5 days) was administered to patients receiving individualized methadone therapy (n=16).<sup>1</sup> No evidence of methadone toxicity or opioid withdrawal was noted during the course of this study.<br><br>The likely mechanism of this interaction is voriconazole inhibition of methadone metabolism.<sup>2,3</sup> Methadone is primarily metabolized by CYP3A, with some additional involvement of CYP2C9 and CYP2C19.<sup>2</sup> Voriconazole is a strong inhibitor of CYP3A and a weak-moderate inhibitor of CYP2C9 and CYP2C19.<sup>3</sup><br><br>A published case report describes a 60-year-old man who had been recieving methadone for 10 days for the treatment of cancer pain and experienced significant resipiratory depression after two days of intravenous administration of the azole antifungal fluconazole.<sup>4</sup> Other published cases describe patients being treated with methadone who developed QT prolongation and torsades de pointes (TdP) attributed to an interaction with the azole antifungals itraconazole and another involving voriconazole.<sup>5,6</sup> Also, a clinical study of 25 patients receiving maintenance methadone therapy found that the methadone AUC was increased by an average of 35% following the addition of fluconazole (200 mg/day) (n=13).<sup>7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Liu P, Foster G, Labadie R, et al, “Pharmacokinetic Interaction Between Voriconazole and Methadone at Steady State in Patients on Methadone Therapy,” <i>Antimicrob Agents Chemother</i>, 2007, 51(1):110-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17074798\">[PubMed 17074798]</a></p>\n<p>2. Foster DJ, Somogyi AA, Bochner F, “Methadone N-Demethylation in Human Liver Microsomes: Lack of Stereoselectivity and Involvement of CYP3A4,” <i>Br J Clin Pharmacol</i>, 1999, 47(4):403-12. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10233205\">[PubMed 10233205]</a></p>\n<p>3. Prescribing information. VFend (voriconazole). New York, NY: Pfizer Inc, November 2011.</p>\n<p>4. Tarumi Y, Pereira J, Watanabe S, “Methadone and Fluconazole: Respiratory Depression by Drug Interaction,” <i>J Pain Symptom Manage</i>, 2002, 23(2):148-53. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11844635\">[PubMed 11844635]</a></p>\n<p>5. NoorZurani MH, Vicknasingam B, Narayanan S, “Itraconazole-Induced Torsade de Pointes in a Patient Receiving Methadone Substitution Therapy,” <i>Drug Alcohol Rev</i>, 2009, 28(6):688-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19930027\">[PubMed 19930027]</a></p>\n<p>6. Reinhold JA, Sanoski CA, Russo AM, et al, “Torsades de Pointes Associated with Methadone and Voriconazole,” <i>BMJ Case Rep</i>, 2009, pii: bcr07.2009.2119. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22190985\">[PubMed 22190985]</a></p>\n<p>7. Cobb MN, Desai J, Brown LS Jr, et al, “The Effect of Fluconazole on the Clinical Pharmacokinetics of Methadone,” <i>Clin Pharmacol Ther</i>, 1998, 63(6):655-62. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9663180\">[PubMed 9663180]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6758":"<p><b>Title</b> Alcohol (Ethyl) / Tinidazole</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Tinidazole may enhance the adverse/toxic effect of Alcohol (Ethyl). A disulfiram-like reaction may occur. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Tinidazole prescribing information recommends avoiding any alcohol ingestion while using tinidazole and for 3 days after completion of tinidazole treatment. Alcohol may be contained in beverages and pharmaceutical products (e.g., elixirs).</p> \n<p><b>Discussion</b> Tinidazole prescribing information cautions that concurrent use of alcohol with tinidazole may result in a disulfiram-like reaction (i.e., abdominal pain, cramps, nausea, vomiting, headache, flushing) and should be avoided.<sup>1</sup> Of note, no specific data or reports on this reaction are provided.<br><br>Several case reports describe signs and symptoms of a disulfiram-like reaction during coadministration of alcohol and the related nitroimidazole metronidazole.<sup>2,3,4,5,6,7</sup> Reported reactions have ranged from mild cardiovascular effects to death. Randomized, double-blind, placebo-controlled trials, however, have failed to demonstrate the value of metronidazole as an alcohol aversive agent.<sup>8,9,10,11,12,13</sup> The results of these trials suggest that if a reaction does occur, it does so in an unpredictable and relatively mild fashion. The mechanism of a metronidazole-alcohol interaction, if one does occur, is unclear. A disulfiram-like reaction presumes that metronidazole increases acetaldehyde concentrations by inhibiting acetaldehyde dehydrogenase, thereby inhibiting the metabolism of acetaldehyde to acetic acid. A double-blind study involving 12 normal subjects demonstrated no effect of metronidazole on acetaldehyde concentrations.<sup>14</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Tindamax (tinidazole). San Antonio, TX: Mission Pharmacal Company, 8/2007.</p>\n<p>2. Taylor JAT, “Metronidazole - A New Agent for Combined Somatic and Psychic Therapy for Alcoholism: A Case Study and Preliminary Report,” <i>Bull Los Angeles Neurol Soc</i>, 1964, 29:58-62.</p>\n<p>3. Sansoy OM and Vegas L, “ Evaluation of Metronidazole in the Treatment of Alcoholism,” <i>J Indian Med Assoc</i>, 1970, 55:29.</p>\n<p>4. De Mattos H, “Relationship Between Alcoholism and the Digestive System,” <i>Hospital</i>, 1968, 74:281.</p>\n<p>5. Edwards DL, Fink PC, and Van Dyke PO, “ Dislufiram-like Reaction Associated With Intravenous Trimethoprim-Sulfamethoxazole and Metronidazole,” <i>Clin Pharm</i>, 1986, 5(12):999-1000.</p>\n<p>6. Plosker GL, “Possible Interaction Between Ethanol and Vaginally Administered Metronidazole,” <i>Clin Pharm</i>, 1987, 6(3):189,192-3.</p>\n<p>7. Cina SJ, Russell RA, and Conradi SE, “Sudden Death Due to Metronidazole/Ethanol Interaction,” <i>Am J Forensic Med Pathol</i>, 1996, 17(4):343-6.</p>\n<p>8. Linton PH and Hain JD, “Metronidazole in the Treatment of Alcoholism,” <i>Quarterly J Stud Alcohol</i>, 1967, 28(3):544-6.</p>\n<p>9. Egan WP and Goetz R, “Effect of Metronidazole on Drinking by Alcoholics,” <i>Quarterly J Stud Alcohol</i>, 1968, 29(4):899-902.</p>\n<p>10. Penick SB, Carrier RN, and Sheldon JB, “Metronidazole in the Treatment of Alcoholism,” <i>Am J Psychiatry</i>, 1969, 125(8):1063-6.</p>\n<p>11. Strassman HD, Adams B, and Pearson AW, “Metronidazole Effect on Social Drinkers,” <i>Quarterly J Stud Alcohol</i>, 1970, 31(2):394-8.</p>\n<p>12. Platz A, Panepinto WC, Kissin B, et al, “Metronidazole and Alcoholism,” <i>Dis Nerv Syst</i>, 1970, 31(9):631-6.</p>\n<p>13. Kaplan R, Blume S, Rosenberg S, et al, “Phenytoin, Metronidazole and Multivitamins in the Treatment of Alcoholism,” <i>Quarterly J Stud Alcohol</i>, 1972, 33(1):94-104.</p>\n<p>14. Visapaa JP, Tillonen JS, Kaihovaara PS, et al, “Lack of Disulfiram-like Reaction With Metronidazole and Ethanol,” <i>Ann Pharmacother</i>, 2002, 36(6):971-4.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6759":"<p><b>Title</b> Disulfiram / Tinidazole</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Tinidazole may enhance the adverse/toxic effect of Disulfiram. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the concomitant use of tinidazole and disulfiram. Avoid tinidazole use in patients who have received disulfiram within the previous 2 weeks.</p> \n<p><b>Discussion</b> The prescribing information for tinidazole notes that the related nitroimidazole metronidazole has been associated with psychotic reactions in patients who were also receiving disulfiram and contains a warning to avoid the use of tinidazole in patients who have received disulfiram within the previous 2 weeks.<sup>1,2</sup> In one study, reported in brief, the concomitant use of disulfiram and metronidazole resulted in a high incidence (21%) of CNS toxicities in 29 hospitalized patients.<sup>3,4</sup> Symptoms included acute psychoses, confusion, hallucinations, and/or delusions. No such toxicity was seen in 29 patients treated with disulfiram alone.<br><br>Disulfiram is associated with rare development of psychoses. However, the mechanism by which it may contribute to psychosis and the mechanism by which metronidazole or tinidazole may enhance this effect are unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Tindamax (tinidazole). San Antonio, TX: Mission Pharmacal Company, 8/2007.</p>\n<p>2. Prescribing information. Flagyl (metronidazole). Deerfield, IL: Baxter Healthcare Corporation, June 2009.</p>\n<p>3. Rothstein E and Clancy DD, “Toxicity of Disulfiram Combined with Metronidazole,” <i>N Engl J Med</i>, 1969, 280:1006. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4888076\">[PubMed 4888076]</a></p>\n<p>4. Rothstein E and Clancy DD, “Combined Use of Disulfiram and Metronidazole in Treatment of Alcoholism,” <i>Q J Stud Alcohol</i>, 1970, 31(2):446-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4921397\">[PubMed 4921397]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6760":"<p><b>Title</b> Procainamide / LamoTRIgine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> LamoTRIgine may increase the serum concentration of Procainamide. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider monitoring for increased procainamide concentrations and/or systemic effects in patients receiving procainamide with lamotrigine. The lamotrigine Canadian product monograph states that coadministration of these agents is not recommended.</p> \n<p><b>Discussion</b> The lamotrigine Canadian product monograph states that lamotrigine may inhibit OCT2/SLC22A2 mediated renal tubular excretion, and is therefore not recommended in combination with narrow therapeutic index drugs that are substrates of this transporter (citing metformin and procainamide as examples of such substrates).<sup>1</sup> The potential magnitude and severity of this interaction are unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Product monograph. Lamictal (lamotrigine). Mississauga, ON: GlaxoSmithKline Inc., January 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6761":"<p><b>Title</b> MetFORMIN / LamoTRIgine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> LamoTRIgine may increase the serum concentration of MetFORMIN. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider monitoring for increased metformin toxicity (e.g., gastrointestinal effects, weakness, and rarer effects such as lactic acidosis) in patients receiving metformin with lamotrigine. The lamotrigine Canadian product monograph states that coadministration of these drugs is not recommended.</p> \n<p><b>Discussion</b> The lamotrigine Canadian product monograph states that lamotrigine may inhibit OCT2/SLC22A2 mediated renal tubular excretion, and is therefore not recommended in combination with narrow therapeutic index drugs that are substrates of this transporter (citing metformin and procainamide as examples of such drugs).<sup>1</sup> No data are available describing a specific interaction between lamotrigine and metformin. OCT2/SLC22A2 polymorphisms have been associated with as much as a 50% decline in metformin renal clearance, suggesting a significant role of this transporter in metformin disposition.<sup>2,3,4</sup> The largest pharmacogenetic study conducted to date, however, found no significant influence of SLC22A2 polymorphisms on metformin (500 mg single oral dose) renal clearance in a population of 103 healthy volunteers.<sup>5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Product monograph. Lamictal (lamotrigine). Mississauga, ON: GlaxoSmithKline Inc., January 2012.</p>\n<p>2. Song IS, Shin HJ, Shim EJ, et al, “Genetic Variants of the Organic Cation Transporter 2 Influence the Disposition of Metformin,” <i>Clin Pharmacol Ther</i>, 2008, 84(5):559-62. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18401339\">[PubMed 18401339]</a></p>\n<p>3. Wang ZJ, Yin OQ, Tomlinson B, et al, “OCT2 Polymorphisms and In-Vivo Renal Functional Consequence: Studies With Metformin and Cimetidine,” <i>Pharmacogenet Genomics</i>, 2008, 18(7):637-45. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18551044\">[PubMed 18551044]</a></p>\n<p>4. Chen Y, Li S, Brown C, et al, “Effect of Genetic Variation in the Organic Cation Transporter 2 on the Renal Elimination of Metformin,” <i>Pharmacogenet Genomics</i>, 2009, 19(7):497-504. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19483665\">[PubMed 19483665]</a></p>\n<p>5. Tzvetkov MV, Vormfelde SV, Balen D, et al, “The Effects of Genetic Polymorphisms in the Organic Cation Transporters OCT1, OCT2, and OCT3 on the Renal Clearance of Metformin,” <i>Clin Pharmacol Ther</i>, 2009, 86(3):299-306. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19536068\">[PubMed 19536068]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6763":"<p><b>Title</b> Methadone / Itraconazole</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Itraconazole may increase the serum concentration of Methadone. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of itraconazole with methadone is contraindicated according to itraconazole prescribing information.</p> \n<p><b>Discussion</b> A published case describes a patient being treated with methadone who developed QT prolongation and torsades de pointes (TdP) following two doses of itrazonazole (200 mg).<sup>1</sup> Based on this report and data predicting a significant interaction between itraconazole and methadone, the itraconazole prescribing information contraindicates concurrent use with methadone.<sup>2</sup><br><br>The specific mechanism for this interaction is most likely itraconazole inhibition of the CYP3A-mediated metabolism of methadone.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. NoorZurani MH, Vicknasingam B, Narayanan S, “Itraconazole-Induced Torsade de Pointes in a Patient Receiving Methadone Substitution Therapy,” <i>Drug Alcohol Rev</i>, 2009, 28(6):688-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19930027\">[PubMed 19930027]</a></p>\n<p>2. Prescribing information. Sporanox (itraconazole). Raritan, NJ: Centocor Ortho Biotech Products, L.P., November 2011.</p>\n<p>3. Foster DJ, Somogyi AA, Bochner F, “Methadone N-Demethylation in Human Liver Microsomes: Lack of Stereoselectivity and Involvement of CYP3A4,” <i>Br J Clin Pharmacol</i>, 1999, 47(4):403-12. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10233205\">[PubMed 10233205]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6764":"<p><b>Title</b> Methadone / Posaconazole</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Posaconazole may enhance the QTc-prolonging effect of Methadone. Posaconazole may increase the serum concentration of Methadone. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of posaconazole with CYP3A substrates that can prolong the QT interval, such as methadone, is contraindicated according to the posaconazole prescribing information.</p> \n<p><b>Discussion</b> Although specific data regarding this combination are lacking, concurrent use of posaconazole with methadone is contraindicated according to posaconazole prescribing information due to evidence suggesting this combination could result in a clinically significant interaction.<sup>1</sup> Posaconazole is a potent inhibitor of CYP3A4, which appears to be primary enzyme responsible for the metabolism of methadone, and posaconazole may be able to prolong the QT interval, possibly resulting in an additive or synergistic QT-prolonging effect when used with other drugs that can prolong the QT (particularly if that drug is present in high concentrations due to a drug interaction).<sup>1,2</sup> Further, data with other azole antifungals, including many of which with less potent inhibition of CYP3A, describe clinically meaningful interactions with methadone.<sup>3,4,5,6,7</sup><br><br>Two published cases describe patients being treated with methadone who developed QT prolongation and torsades de pointes (TdP) attributed to an interaction with the azole antifungals itraconazole and another involving voriconazole.<sup>3,4</sup> Another published case report describes a 60-year-old man who had been recieving methadone for 10 days for the treatment of cancer pain and experienced significant resipiratory depression after two days of intravenous fluconazole.<sup>5</sup><br><br>The average AUC for (R)- and (S)-methadone were increased 47% and 103%, respectively, when voriconazole (400 mg every 12 hours x 1 day, then 200 mg every 12 hours x 5 days) was administered to patients receiving individualized methadone therapy (n=16).<sup>6</sup> No evidence of methadone toxicity or opioid withdrawal was noted during the course of this study. In another study, the methadone AUC was increased by an average of 35% following the addition of fluconazole (200 mg/day), which is only a moderate inhibitor of CYP3A but is a strong inhibitor of CYP2C9 and CYP2C19 (two other enzymes thought to participate in the metabolism of methadone), to maintenance methadone regimens (n=13).<sup>7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Noxafil (posaconazole). Whitehouse Station, NJ: Merck &amp; Co., Inc., 10/2011.</p>\n<p>2. Foster DJ, Somogyi AA, Bochner F, “Methadone N-Demethylation in Human Liver Microsomes: Lack of Stereoselectivity and Involvement of CYP3A4,” <i>Br J Clin Pharmacol</i>, 1999, 47(4):403-12. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10233205\">[PubMed 10233205]</a></p>\n<p>3. NoorZurani MH, Vicknasingam B, Narayanan S, “Itraconazole-Induced Torsade de Pointes in a Patient Receiving Methadone Substitution Therapy,” <i>Drug Alcohol Rev</i>, 2009, 28(6):688-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19930027\">[PubMed 19930027]</a></p>\n<p>4. Reinhold JA, Sanoski CA, Russo AM, et al, “Torsades de Pointes Associated with Methadone and Voriconazole,” <i>BMJ Case Rep</i>, 2009, pii: bcr07.2009.2119. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22190985\">[PubMed 22190985]</a></p>\n<p>5. Tarumi Y, Pereira J, Watanabe S, “Methadone and Fluconazole: Respiratory Depression by Drug Interaction,” <i>J Pain Symptom Manage</i>, 2002, 23(2):148-53. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11844635\">[PubMed 11844635]</a></p>\n<p>6. Liu P, Foster G, Labadie R, et al, “Pharmacokinetic Interaction Between Voriconazole and Methadone at Steady State in Patients on Methadone Therapy,” <i>Antimicrob Agents Chemother</i>, 2007, 51(1):110-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17074798\">[PubMed 17074798]</a></p>\n<p>7. Cobb MN, Desai J, Brown LS Jr, et al, “The Effect of Fluconazole on the Clinical Pharmacokinetics of Methadone,” <i>Clin Pharmacol Ther</i>, 1998, 63(6):655-62. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9663180\">[PubMed 9663180]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6765":"<p><b>Title</b> Methadone / Fluconazole</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Fluconazole may enhance the QTc-prolonging effect of Methadone. Fluconazole may increase the serum concentration of Methadone. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor patients closely for evidence of methadone toxicities, including but not limited to respiratory depression and QT prolongation/torsades de pointes, if combined with fluconazole. Methadone dose reductions may be required.</p> \n<p><b>Discussion</b> A published case report describes a 60-year-old man who had been receiving methadone for 10 days for the treatment of cancer pain and experienced significant respiratory depression after two days of intravenous fluconazole.<sup>1</sup> Another case report describes a 17-year-old female taking high-dose methadone who experienced QTc prolongation after the addition of fluconazole and tricyclic antidepressants.<sup>2</sup> Her QTc normalized after fluconazole discontinuation. Further, a clinical study of 25 patients receiving maintenance methadone therapy found that the methadone AUC increased by an average of 35% following the addition of fluconazole (200 mg/day) in 13 patients.<sup>3</sup><br><br>The likely mechanism of this interaction is fluconazole inhibition of methadone metabolism.<sup>4,5</sup> Methadone is primarily metabolized by CYP3A, with some additional involvement of CYP2C9 and CYP2C19.<sup>4</sup> Fluconazole is a moderate inhibitor of CYP3A and an inhibitor of CYP2C9 and CYP2C19.<sup>5</sup><br><br>Other published cases describe patients treated with methadone who developed QT prolongation and torsades de pointes attributed to an interaction with the azole antifungals itraconazole and another involving voriconazole.<sup>6,7</sup> Another clinical study reported that the average AUC for (R)- and (S)-methadone increased 47% and 103%, respectively, when voriconazole (400 mg every 12 hours x 1 day, then 200 mg every 12 hours x 5 days) was administered to patients receiving individualized methadone therapy (n=16).<sup>8</sup> No evidence of methadone toxicity or opioid withdrawal was noted during the study.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Tarumi Y, Pereira J, Watanabe S. Methadone and fluconazole: respiratory depression by drug interaction. <i>J Pain Symptom Manage</i>. 2002;23(2):148-153. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11844635\">[PubMed 11844635]</a></p>\n<p>2. Rasmussen VF, Lundberg V, Jespersen TW, Hasle H. Extreme doses of intravenous methadone for severe pain in two children with cancer. <i>Pediatr Blood Cancer</i>. 2015;62(6):1087-1090. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25641929\">[PubMed 25641929]</a></p>\n<p>3. Cobb MN, Desai J, Brown LS Jr, Zannikos PN, Rainey PM. The effect of fluconazole on the clinical pharmacokinetics of methadone. <i>Clin Pharmacol Ther</i>. 1998;63(6):655-662. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9663180\">[PubMed 9663180]</a></p>\n<p>4. Foster DJ, Somogyi AA, Bochner F. Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4. <i>Br J Clin Pharmacol</i>. 1999;47(4):403-412. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10233205\">[PubMed 10233205]</a></p>\n<p>5. Diflucan (fluconazole) [prescribing information]. New York, NY: Pfizer Inc; June 2011.</p>\n<p>6. NoorZurani MH, Vicknasingam B, Narayanan S. Itraconazole-induced torsade de pointes in a patient receiving methadone substitution therapy. <i>Drug Alcohol Rev</i>. 2009;28(6):688-690. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19930027\">[PubMed 19930027]</a></p>\n<p>7. Reinhold JA, Sanoski CA, Russo AM, Cooper JM, Spinler SA. Torsades de pointes associated with methadone and voriconazole [published online December 22, 2009]. <i>BMJ Case Rep</i>. doi: 10.1136/bcr.07.2009.2119. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22190985\">[PubMed 22190985]</a></p>\n<p>8. Liu P, Foster G, Labadie R, Somoza E, Sharma A. Pharmacokinetic interaction between voriconazole and methadone at steady state in patients on methadone therapy. <i>Antimicrob Agents Chemother</i>. 2007;51(1):110-118. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17074798\">[PubMed 17074798]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6767":"<p><b>Title</b> Methadone / Ketoconazole (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Ketoconazole (Systemic) may increase the serum concentration of Methadone. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of methadone and systemic ketoconazole. Ketoconazole U.S. prescribing information specifically lists this as a contraindication.</p> \n<p><b>Discussion</b> Although specific data regarding this combination are lacking, concurrent use of ketoconazole with methadone is expected to result in a clinically significant interaction. Ketoconazole is a potent inhibitor of CYP3A4, which appears to be primary enzyme responsible for the metabolism of methadone.<sup>1,2</sup> Further, data with other azole antifungals, including many of which that are less potent inhibitors of CYP3A, describe clinically meaningful interactions with methadone.<sup>3,4,5,6,7</sup><br><br>Two published cases describe patients being treated with methadone who developed QT prolongation and torsades de pointes (TdP) attributed to an interaction with the azole antifungals itraconazole and another involving voriconazole.<sup>3,4</sup> Another published case report describes a 60-year-old man who had been recieving methadone for 10 days for the treatment of cancer pain and experienced significant resipiratory depression after two days of intravenous fluconazole.<sup>5</sup><br><br>The average AUC for (R)- and (S)-methadone were increased 47% and 103%, respectively, when voriconazole (400 mg every 12 hours x 1 day, then 200 mg every 12 hours x 5 days) was administered to patients receiving individualized methadone therapy (n=16).<sup>6</sup> No evidence of methadone toxicity or opioid withdrawal was noted during the course of this study. In another study, the methadone AUC was increased by an average of 35% following the addition of fluconazole (200 mg/day), which is only a moderate inhibitor of CYP3A but is a strong inhibitor of CYP2C9 and CYP2C19 (two other enzymes thought to participate in the metabolism of methadone), to maintenance methadone regimens (n=13).<sup>7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Nizoral</i> (ketoconazole) [prescribing information]. Titusville, NJ: Janssen Pharmaceutica; February 2014.</p>\n<p>2. Foster DJ, Somogyi AA, Bochner F, “Methadone N-Demethylation in Human Liver Microsomes: Lack of Stereoselectivity and Involvement of CYP3A4,” <i>Br J Clin Pharmacol</i>, 1999, 47(4):403-12. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10233205\">[PubMed 10233205]</a></p>\n<p>3. NoorZurani MH, Vicknasingam B, Narayanan S, “Itraconazole-Induced Torsade de Pointes in a Patient Receiving Methadone Substitution Therapy,” <i>Drug Alcohol Rev</i>, 2009, 28(6):688-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19930027\">[PubMed 19930027]</a></p>\n<p>4. Reinhold JA, Sanoski CA, Russo AM, et al, “Torsades de Pointes Associated with Methadone and Voriconazole,” <i>BMJ Case Rep</i>, 2009, pii: bcr07.2009.2119. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22190985\">[PubMed 22190985]</a></p>\n<p>5. Tarumi Y, Pereira J, Watanabe S, “Methadone and Fluconazole: Respiratory Depression by Drug Interaction,” <i>J Pain Symptom Manage</i>, 2002, 23(2):148-53. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11844635\">[PubMed 11844635]</a></p>\n<p>6. Liu P, Foster G, Labadie R, et al, “Pharmacokinetic Interaction Between Voriconazole and Methadone at Steady State in Patients on Methadone Therapy,” <i>Antimicrob Agents Chemother</i>, 2007, 51(1):110-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17074798\">[PubMed 17074798]</a></p>\n<p>7. Cobb MN, Desai J, Brown LS Jr, et al, “The Effect of Fluconazole on the Clinical Pharmacokinetics of Methadone,” <i>Clin Pharmacol Ther</i>, 1998, 63(6):655-62. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9663180\">[PubMed 9663180]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6768":"<p><b>Title</b> MitoMYcin (Systemic) / Antineoplastic Agents (Vinca Alkaloids)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Antineoplastic Agents (Vinca Alkaloids) may enhance the adverse/toxic effect of MitoMYcin (Systemic). Specifically, the risk of pulmonary toxicity may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients closely for signs and symptoms of pulmonary toxicity. Acute shortness of breath and severe bronchospasm have been reported following use of this combination and may require aggressive treatment, particularly when there is pre-existing pulmonary dysfunction.</p>\n<div>\n <p><b>Antineoplastic Agents (Vinca Alkaloids) Interacting Members</b> VinBLAStine, VinCRIStine, VinCRIStine (Liposomal), Vindesine, Vinflunine, Vinorelbine</p>\n</div> \n<p><b>Discussion</b> Several reports describe acute pulmonary toxicity associated with the combined use of mitomycin with a vinca alkaloid (vindesine,<sup>1,2,3</sup> vinblastine,<sup>1,3,4,5,6</sup> vincristine,<sup>7</sup> or vinorelbine<sup>8,9</sup>). When specified, the onset of symptoms was temporally related to administration of the vinca alkaloid, generally occurring within 1-5 hours of administration.<sup>2,3,6,8</sup> Toxicities were usually characterized as rapidly reversible and highly responsive to glucocorticoid administration;<sup>2,7,9</sup> although, some reports have described chronic sequelae,<sup>1</sup> only partial glucocorticoid responsiveness,<sup>1</sup> and fatal outcomes.<sup>5</sup><br><br>Of note, one study of 133 patients with squamous cell carcinoma of the lung reported a similar rate of pulmonary toxicity between those randomized to mitomycin plus vinblastine plus cisplatin and those randomized to mitomycin alone.<sup>10</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Rivera MP, Kris MG, Gralla RJ, et al, “Syndrome of Acute Dyspnea Related to Combined Mitomycin Plus Vinca Alkaloid Chemotherapy,” <i>Am J Clin Oncol</i>, 1995, 18:245-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7747713\">[PubMed 7747713]</a> </p>\n<p>2. Luedke D, McLaughlin TT, Daughaday C, et al, “Mitomycin C and Vindesine Associated Pulmonary Toxicity with Variable Clinical Expression,” <i>Cancer</i>, 1985, 55:542-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3917366\">[PubMed 3917366]</a> </p>\n<p>3. Kris MG, Pablo D, Gralla RJ, et al, “Dyspnea Following Vinblastine or Vindesine Administration in Patients Receiving Mitomycin Plus Vinca Alkaloid Combination Therapy,” <i>Cancer Treat Rep</i>, 1984, 68:1029-31. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6744336\">[PubMed 6744336]</a> </p>\n<p>4. Hoelzer KL, Harrison BR, Luedke SW, et al, “Vinblastine-Associated Pulmonary Toxicity in Patients Receiving Combination Therapy with Mitomycin and Cisplatin,” <i>Drug Intell Clin Pharm</i>, 1986, 20:287-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3698826\">[PubMed 3698826]</a> </p>\n<p>5. Rao SX, Ramaswamy G, Levin M, et al, “Fatal Acute Respiratory Failure after Vinblastine-Mitomycin Therapy in Lung Carcinoma,” <i>Arch Intern Med</i>, 1985, 145:1905-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4037952\">[PubMed 4037952]</a> </p>\n<p>6. Konits PH, Aisner J, Sutherland JC, et al, “Possible Pulmonary Toxicity Secondary to Vinblastine,” <i>Cancer</i>, 1982, 50:2771-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7139567\">[PubMed 7139567]</a> </p>\n<p>7. Chang AY, Kuebler JP, Pandya KJ, et al, “Pulmonary Toxicity Induced by Mitomycin C Is Highly Responsive to Glucocorticoids,” <i>Cancer</i>, 1986, 57:2285-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3084059\">[PubMed 3084059]</a> </p>\n<p>8. Raderer M, Kornek G, Hejna M, et al, “Acute Pulmonary Toxicity Associated with High-Dose Vinorelbine and Mitomycin C,” <i>Ann Oncol</i>, 1996, 7:973-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9006751\">[PubMed 9006751]</a> </p>\n<p>9. Kornek GV, Haider K, Kwasny W, et al, “Effective Treatment of Advanced Breast Cancer with Vinorelbine, Mitomycin C Plus Human Granulocyte Colony-Stimulating Factor,” <i>Br J Cancer</i>, 1996, 74:1668-73. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8932353\">[PubMed 8932353]</a> </p>\n<p>10. Castro M, Veeder MH, Mailliard JA, et al, “A Prospective Study of Pulmonary Function in Patients Receiving Mitomycin,” <i>Chest</i>, 1996, 109:939-44. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8635374\">[PubMed 8635374]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6769":"<p><b>Title</b> Itraconazole / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Itraconazole. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> The use of itraconazole concurrently with or within 2 weeks of any CYP3A4 inducer is not recommended. If such a combination can not be avoided, monitor patients closely for evidence of diminished clinical response to itraconazole.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> The AUC of itraconazole (single 200 mg dose) was reduced by more than 90% in 15 healthy subjects when administered following a 15-day course of the CYP3A inducer phenytoin (300 mg/day).<sup>1</sup> In another study, 8 of 9 subjects receiving itraconazole had undetectable itraconazole concentrations following treatment with the potent CYP3A inducer rifampin (600 mg/day x 14 days).<sup>2</sup> Several additional case reports describe significantly decreased itraconazole concentrations and/or therapeutic failure/relapse with itraconazole when concurrently receiving the CYP3A inducers phenytoin, phenobarbital, and/or carbamazepine.<sup>3,4,5</sup> Because of these concerns about the potential for diminished itraconazole concentrations and impaired clinical effectiveness, the itraconazole prescribing information does not recommend concurrent use of any strong CYP3A inducer.<sup>6</sup><br><br>The mechanism for this interaction is increased metabolism of itraconazole and/or hydroxyitraconazole via induction of the CYP3A enzyme primarily responsible for itraconazole metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ducharme MP, Slaughter RL, Warbasse LH, et al, “Itraconazole and Hydroxyitraconazole Serum Concentrations are Reduced More than Tenfold by Phenytoin,” <i>Clin Pharmacol Ther</i>, 1995, 58(6):617-24. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8529326\">[PubMed 8529326]</a></p>\n<p>2. Hay RJ, Clayton YM, Moore MK, et al, “An Evaluation of Itraconazole in the Management of Onychomycosis,” <i>Br J Dermatol</i>, 1988, 119:359-66. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2846030\">[PubMed 2846030]</a></p>\n<p>3. Tucker RM, Denning DW, Hanson LH, et al, “Interaction of Azoles with Rifampin, Phenytoin, and Carbamazepine: In Vitro and Clinical Observations,” <i>Clin Infect Dis</i>, 1992, 14(1):165-74. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1315160\">[PubMed 1315160]</a></p>\n<p>4. Bonay M, Jonville-Bera AP, Diot P, et al, “Possible Interaction between Phenobarbital, Carbamazepine and Itraconazole,” <i>Drug Saf</i>, 1993, 9(4):309-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8260123\">[PubMed 8260123]</a></p>\n<p>5. Jaruratanasirikul S, Sriwiriyajan S, “Effect of Rifampicin on the Pharmacokinetics of Itraconazole in Normal Volunteers and AIDS Patients,” <i>Eur J Clin Pharmacol</i>, 1998, 54(2):155-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9626920\">[PubMed 9626920]</a></p>\n<p>6. <i>Sporanox</i> (itraconazole) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals; June 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6771":"<p><b>Title</b> Ketoconazole (Systemic) / Isoniazid</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Isoniazid may decrease the serum concentration of Ketoconazole (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor clinical response to ketoconazole closely when used with isoniazid. Specifically, monitor patients for evidence of diminished clinical response to ketoconazole.</p> \n<p><b>Discussion</b> Multiple case reports describe apparent ketoconazole treatment failures attributed to an interaction with isoniazid (with or without rifampin).<sup>1,2</sup> In one of these reports, serum ketoconazole concentrations were approximately 80% lower with concurrent isoniazid.<sup>1</sup> A small study of 8 patients with tuberculosis similarly reported an average decrease in ketoconazole concentrations of 75% at 2 hours and 85% at 4 hours with concurrent isoniazid (5 mg/kg).<sup>3</sup><br><br>The specific mechanism of this interaction is unknown. Isoniazid is a potential inducer of CYP2E1 but is not known to be an inducer of other cytochrome P450 enzymes or other drug metabolizing enzymes/drug transporters.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Engelhard D, Stutman HR, Marks MI, “Interaction of Ketoconazole with Rifampin and Isoniazid,” <i>N Engl J Med</i>, 1984, 311(26):1681-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6095080\">[PubMed 6095080]</a></p>\n<p>2. Abadie-Kemmerly S, Pankey GA, Dalovisio JR, “Failure of Ketoconazole Treatment of Blastomyces dermatitidis [corrected] Due to Interaction of Isoniazid and Rifampin,” <i>Ann Intern Med</i>, 1988, 109(10):844-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3190036\">[PubMed 3190036]</a></p>\n<p>3. Pilheu JA, Galati MR, Yunis AS, et al, [“Pharmacokinetic Interaction of Ketoconazole, Isoniazid and Rifampicin,”] <i>Medicina (B Aires)</i>, 1989, 49(1):43-7. (article in Spanish) <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2698437\">[PubMed 2698437]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6772":"<p><b>Title</b> Itraconazole / Isoniazid</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Isoniazid may decrease the serum concentration of Itraconazole. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor clinical response to itraconazole closely when used with isoniazid. Specifically, monitor patients for evidence of diminished clinical response to itraconazole.</p> \n<p><b>Discussion</b> The itraconazole prescribing information cautions that concurrent use of isoniazid may be associated with a decrease in itraconazole concentrations, though it is noted that there are no specific clinical data regarding the use of this combination.<sup>1</sup><br><br>The presumed mechanism for this predicted interaction appears to be induction of itraconazole metabolism, a prediction that appears to be the result of an extrapolation of the reported interaction between ketoconazole and isoniazid.<sup>2,3,4</sup> Multiple case reports describe apparent ketoconazole treatment failures attributed to an interaction with isoniazid (with or without rifampin).<sup>2,3</sup> In one of these reports, serum ketoconazole concentrations were approximately 80% lower with concurrent isoniazid.<sup>1</sup> A small study of 8 patients with tuberculosis similarly reported an average decrease in ketoconazole concentrations of 75% at 2 hours and 85% at 4 hours with concurrent isoniazid (5 mg/kg).<sup>4</sup> The specific mechanism of this interaction is unknown. Isoniazid is a potential inducer of CYP2E1 but is not known to be an inducer of other cytochrome P450 enzymes or other drug metabolizing enzymes/drug transporters.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Sporanox (itraconazole). Raritan, NJ: Centocor Ortho Biotech Products, L.P., November 2011.</p>\n<p>2. Engelhard D, Stutman HR, Marks MI, “Interaction of Ketoconazole with Rifampin and Isoniazid,” <i>N Engl J Med</i>, 1984, 311(26):1681-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6095080\">[PubMed 6095080]</a></p>\n<p>3. Abadie-Kemmerly S, Pankey GA, Dalovisio JR, “Failure of Ketoconazole Treatment of Blastomyces dermatitidis [corrected] Due to Interaction of Isoniazid and Rifampin,” <i>Ann Intern Med</i>, 1988, 109(10):844-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3190036\">[PubMed 3190036]</a></p>\n<p>4. Pilheu JA, Galati MR, Yunis AS, et al, [“Pharmacokinetic Interaction of Ketoconazole, Isoniazid and Rifampicin,”] <i>Medicina (B Aires)</i>, 1989, 49(1):43-7. (article in Spanish) <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2698437\">[PubMed 2698437]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6773":"<p><b>Title</b> CYP3A4 Substrates (High risk with Inhibitors) / Everolimus</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Everolimus may increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>CYP3A4 Substrates (High risk with Inhibitors) Interacting Members</b> Abemaciclib, Acalabrutinib, Ado-Trastuzumab Emtansine, Alfentanil, Alfuzosin, Alitretinoin (Systemic), ALPRAZolam, Amiodarone, AmLODIPine, Aprepitant, ARIPiprazole, ARIPiprazole Lauroxil, Asunaprevir, Atazanavir, AtorvaSTATin, Avanafil, Axitinib, Barnidipine, Benidipine, Benzhydrocodone, Blonanserin, Bosutinib, Brexpiprazole, Brigatinib, Bromocriptine, Bromperidol, Budesonide (Systemic), Buprenorphine, BusPIRone, Cabazitaxel, Cabozantinib, Calcitriol (Systemic), CarBAMazepine, Cariprazine, Ceritinib, ChlordiazePOXIDE, Chloroquine, Cilnidipine, Cilostazol, Cinacalcet, Cisapride, Citalopram, Clarithromycin, ClonazePAM, Cobimetinib, Colchicine, Conivaptan, Copanlisib, Crizotinib, CycloSPORINE (Systemic), Cyproterone, Dabrafenib, Daclatasvir, Dapoxetine, Darifenacin, Darunavir, Dasatinib, Deflazacort, Dexamethasone (Systemic), DiazePAM, Digitoxin, Dihydroergotamine, DilTIAZem, Disopyramide, DOCEtaxel, Domperidone, Doxazosin, DOXOrubicin (Conventional), DOXOrubicin (Liposomal), Dronedarone, Dydrogesterone, Ebastine, Elbasvir, Eletriptan, Eliglustat, Eplerenone, Ergoloid Mesylates, Ergonovine, Ergotamine, Erlotinib, Erythromycin (Systemic), Escitalopram, Eszopiclone, Ethosuximide, Etizolam, Everolimus, Felbamate, Felodipine, FentaNYL, Fesoterodine, Flibanserin, Flurazepam, Fluticasone (Oral Inhalation), Fosaprepitant, Gefitinib, Grazoprevir, GuanFACINE, Halofantrine, Haloperidol, HYDROcodone, HYDROXYprogesterone Caproate, Ibrutinib, Irinotecan (Conventional), Irinotecan (Liposomal), Isavuconazonium Sulfate, Isosorbide Dinitrate, Isosorbide Mononitrate, Isradipine, Itraconazole, Ivabradine, Ivacaftor, Ixabepilone, Ketamine, Lacidipine, Lapatinib, Lercanidipine, Levomilnacipran, Lidocaine (Systemic), Lidocaine (Topical), Lomitapide, Lovastatin, Lurasidone, Macitentan, Manidipine, Maraviroc, Mefloquine, Methadone, Methylergonovine, Midazolam, Midostaurin, MiFEPRIStone, Mirodenafil, Mirtazapine, Naloxegol, Nefazodone, Neratinib, NiCARdipine, NIFEdipine, Nilotinib, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Olaparib, Olmutinib, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, OxyCODONE, PACLitaxel (Conventional), PACLitaxel (Protein Bound), Palbociclib, Panobinostat, PAZOPanib, Pimavanserin, Pimozide, Piperaquine, Praziquantel, QUEtiapine, QuiNIDine, QuiNINE, Radotinib, Ranolazine, Reboxetine, Regorafenib, Ribociclib, Rupatadine, Ruxolitinib, Salmeterol, SAXagliptin, Sildenafil, Silodosin, Simeprevir, Simvastatin, Sirolimus, Solifenacin, Sonidegib, Stiripentol, SUFentanil, SUNItinib, Suvorexant, Tacrolimus (Systemic), Tadalafil, Tamoxifen, Tamsulosin, Telaprevir, Telithromycin, Temsirolimus, Teniposide, Tezacaftor, TiaGABine, Tofacitinib, Tolterodine, Tolvaptan, Trabectedin, TraZODone, Triazolam, Trimipramine, Udenafil, Valbenazine, Vardenafil, Vemurafenib, Venetoclax, Venlafaxine, Verapamil, VinBLAStine, VinCRIStine, VinCRIStine (Liposomal), Vinflunine, Vinorelbine, Zopiclone</p>\n</div> \n<p><b>Discussion</b> According to the everolimus prescribing information, concurrent use with oral midazolam was associated with an average 30% increase in midazolam AUC and an average 25% increase in midazolam maximum serum concentration (Cmax) in a study of healthy volunteers.<sup>1</sup><br><br>Midazolam is considered a sensitive substrate for CYP3A4, often used in studies to detect CYP3A4 inhibition or induction. In vitro data suggest that everolimus is a competitive inhibitor of CYP3A,<sup>1</sup> making inhibition of the CYP3A-mediated metabolism (in the intestines and/or in the liver) of midazolam the likely mechanism for this observed interaction. Considering the magnitude of the interaction, this degree of inhibition is unlikely to be of clinical relevance for most CYP3A substrates.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Afinitor (everolimus). East Hanover, NJ: Novartis Pharmaceuticals Corporation, March 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6774":"<p><b>Title</b> Vitamin K Antagonists / Ivermectin (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ivermectin (Systemic) may enhance the anticoagulant effect of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor response to warfarin or other vitamin K antagonists closely (i.e., INR) and watch for signs and symptoms of bleeding when patients are treated with ivermectin. Due to ivermectin's long half-life, the effects of any interaction could persist for several days following the final ivermectin dose.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin</p>\n</div> \n<p><b>Discussion</b> One report described 28 patients who experienced progressively elevated prothrombin times (PT) at 3, 7, and 30 days after a single dose of ivermectin (150 mcg/kg).<sup>1</sup> Two patients developed large hematomas, and one of these patients required a blood transfusion. Other coagulation measures and all indices of liver function were normal, and no patients were receiving other medications. Similarly, a study of ivermectin vs. placebo in 148 patients found that more patients receiving ivermectin experienced an elevated PT than in the placebo group, though the difference was not statistically significant.<sup>2</sup><br><br>In contrast to these reports, a study of 30 adult patients who all received a single baseline dose of ivermectin (20 mcg/kg) found no difference in PT among groups receiving subsequent therapy consisting of ivermectin 200 mcg/kg x1, ivermectin 200 mcg/kg x2, or diethylcarbamazine (72 mg/kg over 12 days).<sup>3</sup> PT (and PTT) values were not different among the groups at 5 days following the baseline dose or at 13 days after administration of the subsequent therapy. Additionally, an in vitro study using blood from human volunteers found no effect of ivermectin at therapeutic concentrations on PT or PTT.<sup>4</sup><br><br>With the exception of two patients from one study,<sup>1</sup> no published reports have described clinically relevant complications resulting from this possible interaction. The mechanism of this potential interaction is uncertain, but data showing a possible inhibitory effect of ivermectin on factor II and factor VII concentrations<sup>2</sup> support a possible anti-vitamin K effect of ivermectin.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Homeida MM, Bagi IA, Ghalib HW, et al, “Prolongation of Prothrombin Time with Ivermectin,” <i>Lancet</i>, 1988, 1(8598):1346-7.</p>\n<p>2. Whitworth JA, Hay CR, McNicholas AM, et al, “Coagulation Abnormalities and Ivermectin,” <i>Ann Trop Med Parasitol</i>, 1992, 86(3):301-5.</p>\n<p>3. Richards Jr FO, McNeeley MB, Bryan RT, “Ivermectin and Prothrombin Time,” <i>Lancet</i>, 1989, 1(8647):1139-40.</p>\n<p>4. Hay J, Arnott MA, “Ivermectin and Coagulation: An In Vitro Study,” <i>Ann Trop Med Parasitol</i>, 1990, 84(5):503-6.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6775":"<p><b>Title</b> Angiotensin-Converting Enzyme Inhibitors / Aliskiren</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Indication</b>: This combination is contraindicated in patients with diabetes.</p></li>\n <li><p><b>Renal Function</b> (CL<sub>cr</sub>&lt;60 mL/min): This combination should generally be avoided in most patients, particularly in patients with a CrCl less than 60 mL/min. Some non-U.S. labeling specifically lists use in patients with a CrCL less than 60 mL/min as contraindicated.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Aliskiren may enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. Aliskiren may enhance the hypotensive effect of Angiotensin-Converting Enzyme Inhibitors. Aliskiren may enhance the nephrotoxic effect of Angiotensin-Converting Enzyme Inhibitors. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> The combination of aliskiren and an angiotensin-converting enzyme (ACE) inhibitor or angiotensin-receptor blocker (ARB) in patients with diabetes is contraindicated. Concomitant use should generally be avoided in other patient populations, particularly those with a creatinine clearance (CrCl) less than 60 mL/min, due to an increased risk of hypotension, hyperkalemia, and kidney dysfunction, as demonstrated in a well-designed clinical trial. If concomitant therapy is deemed necessary, serum potassium, serum creatinine, and blood pressure should be closely monitored.</p>\n<div>\n <p><b>Angiotensin-Converting Enzyme Inhibitors Interacting Members</b> Alacepril, Benazepril, Captopril, Cilazapril, Enalapril, Enalaprilat, Fosinopril, Imidapril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolapril, Zofenopril</p>\n</div> \n<p><b>Discussion</b> Agents that block the renin-angiotensin system (RAS), such as angiotensin-converting enzyme (ACE) inhibitors, angiotensin-receptor blockers (ARBs), and the direct renin inhibitor aliskiren are effective antihypertensives. Monotherapy with ACE inhibitors or ARBs has been shown to reduce albuminuria and slow progression of kidney disease in patients with diabetic kidney disease.<sup>1</sup> Early studies of combined ACE inhibitor and ARB therapy in diabetic kidney disease demonstrated a greater reduction in albuminuria compared to therapy with either agent alone.<sup>2</sup> Subsequent trials, however, demonstrated worse renal outcomes with combined ACE inhibitor and ARB therapy.<sup>3</sup><br><br>Similar to trials with combination ACE inhibitors and ARBs, an early trial of dual RAS blockade with aliskiren and an ARB demonstrated a reduction in albuminuria in diabetic patients. In the AVOID trial, 599 patients with type 2 diabetes and nephropathy received aliskiren or placebo added to losartan therapy. Aliskiren resulted in a statistically significant 20% greater reduction in albuminuria compared with placebo.<sup>4</sup> A subsequent post hoc analysis of this trial concluded that this effect was independent of changes in blood pressure.<sup>5</sup> <br><br>In the ALTITUDE trial, 8,561 patients with type 2 diabetes and chronic kidney disease were randomized to receive aliskiren or placebo in addition to ACE inhibitor or ARB therapy. The primary outcome was a composite of both cardiovascular and renal events, including end-stage renal disease, death, need for renal replacement therapy, or a doubling of the baseline serum creatinine. The trial was stopped prematurely (median follow up 32.9 months) after the data monitoring committee found a trend toward higher cardiovascular events and a higher rate of hypotension, hyperkalemia, and kidney dysfunction.<sup>6</sup> Similar results were seen in the ASPIRE trial in which 820 post-myocardial infarction patients were randomized to receive aliskiren or placebo in addition to standard therapy including an ACE inhibitor or an ARB. No differences in efficacy outcomes including measures of left ventricular remodeling, cardiovascular death, and hospitalization for heart failure were demonstrated. There was, however, a higher rate of adverse events including hypotension, hyperkalemia, and an increase in serum creatinine.<sup>7</sup><br><br>In April 2012, the US Food and Drug Administration issued a drug safety communication warning that the use of aliskiren with either ACE inhibitors or ARBs is contraindicated in patients with diabetes and should be avoided in patients with moderate to severe renal dysfunction (CrCl below 60 mL/min).<sup>8</sup> The aliskiren US prescribing information also reflects this recommendation and adds that this combination should generally be avoided in all patients.<sup>9</sup> Monitor serum potassium, serum creatinine, and blood pressure closely if the combination is used.</p> \n<p><b>Footnotes</b> </p>\n<p>1. American Diabetes Association. Standards of medical care in diabetes--2013. <i>Diabetes Care</i>. 2013;36(suppl 1:)S11-S66. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23264422\">[PubMed 23264422]</a></p>\n<p>2. Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. <i>Ann Intern Med</i>. 2008;148(1):30-48. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17984482\">[PubMed 17984482]</a></p>\n<p>3. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. <i>N Engl J Med</i>. 2008;358(15):1547-1559. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18378520\">[PubMed 18378520]</a></p>\n<p>4. AVOID Study Investigators, Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. <i>N Engl J Med</i>. 2008;358(23):2433-2446. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18525041\">[PubMed 18525041]</a></p>\n<p>5. Persson F, Lewis JB, Lewis EJ, Rossing P, Hollenberg NK, Parving HH. Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy. <i>Clin J Am Soc Nephrol</i>. 2011;6(5):1025-1031. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21350110\">[PubMed 21350110]</a></p>\n<p>6. Parving HH, Brenner BM, McMurray JJ, et al.; ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. <i>N Engl J Med</i>. 2012;367(23):2204-2213. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23121378\">[PubMed 23121378]</a></p>\n<p>7. Solomon SD, Shin SH, Shah A, et al.; Aliskiren Study in Post-MIPatients to Reduce Remodeling (ASPIRE) Investigators. Effect of the direct renin inhibitor aliskiren on left ventricular remodeling following myocardial infarction with systolic dysfunction. <i>Eur Heart J</i>. 2011;32(10):1227-1234. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21317148\">[PubMed 21317148]</a></p>\n<p>8. US Food and Drug Administration. FDA Drug Safety Communication: new warning and contraindication for blood pressure medicines containing aliskiren (Tekturna). http://www.fda.gov/drugs/drugsafety/ucm300889.htm. Updated February 15, 2013. Accessed October 11, 2013.</p>\n<p>9. <i>Tekturna</i> (aliskiren) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; March 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6776":"<p><b>Title</b> Angiotensin II Receptor Blockers / Aliskiren</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Indication</b>: This combination is contraindicated in patients with diabetes.</p></li>\n <li><p><b>Renal Function</b> (CL<sub>cr</sub>&lt;60 mL/min): This combination should generally be avoided in most patients, particularly in patients with a CrCl less than 60 mL/min. Canadian product labeling specifically lists use in patients with a CrCL less than 60 mL/min as contraindicated.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Aliskiren may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the hypotensive effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the nephrotoxic effect of Angiotensin II Receptor Blockers. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> The combination of aliskiren and an angiotensin-converting enzyme (ACE) inhibitor or angiotensin-receptor blocker (ARB) in patients with diabetes is contraindicated. Concomitant use should generally be avoided in other patient populations, particularly those with a creatinine clearance (CrCl) less than 60 mL/min, due to an increased risk of hypotension, hyperkalemia, and kidney dysfunction, as demonstrated in a well-designed clinical trial. If concomitant therapy is deemed necessary, serum potassium, serum creatinine, and blood pressure should be closely monitored.</p>\n<div>\n <p><b>Angiotensin II Receptor Blockers Interacting Members</b> Azilsartan, Candesartan, Eprosartan, Fimasartan, Irbesartan, Losartan, Olmesartan, Telmisartan, Valsartan</p>\n</div> \n<p><b>Discussion</b> Agents that block the renin-angiotensin system (RAS), such as angiotensin-converting enzyme (ACE) inhibitors, angiotensin-receptor blockers (ARBs), and the direct renin inhibitor aliskiren are effective antihypertensives. Monotherapy with ACE inhibitors or ARBs has been shown to reduce albuminuria and slow progression of kidney disease in patients with diabetic kidney disease.<sup>1</sup> Early studies of combined ACE inhibitor and ARB therapy in diabetic kidney disease demonstrated a greater reduction in albuminuria compared to therapy with either agent alone.<sup>2</sup> Subsequent trials, however, demonstrated worse renal outcomes with combined ACE inhibitor and ARB therapy.<sup>3</sup><br><br>Similar to trials with combination ACE inhibitors and ARBs, an early trial of dual RAS blockade with aliskiren and an ARB demonstrated a reduction in albuminuria in diabetic patients. In the AVOID trial, 599 patients with type 2 diabetes and nephropathy received aliskiren or placebo added to losartan therapy. Aliskiren resulted in a statistically significant 20% greater reduction in albuminuria compared with placebo.<sup>4</sup> A subsequent post hoc analysis of this trial concluded that this effect was independent of changes in blood pressure.<sup>5</sup> <br><br>In the ALTITUDE trial, 8,561 patients with type 2 diabetes and chronic kidney disease were randomized to receive aliskiren or placebo in addition to ACE inhibitor or ARB therapy. The primary outcome was a composite of both cardiovascular and renal events, including end-stage renal disease, death, need for renal replacement therapy, or a doubling of the baseline serum creatinine. The trial was stopped prematurely (median follow up 32.9 months) after the data monitoring committee found a trend toward higher cardiovascular events and a higher rate of hypotension, hyperkalemia, and kidney dysfunction.<sup>6</sup> Similar results were seen in the ASPIRE trial in which 820 post-myocardial infarction patients were randomized to receive aliskiren or placebo in addition to standard therapy including an ACE inhibitor or an ARB. No differences in efficacy outcomes including measures of left ventricular remodeling, cardiovascular death, and hospitalization for heart failure were demonstrated. There was, however, a higher rate of adverse events including hypotension, hyperkalemia, and an increase in serum creatinine.<sup>7</sup><br><br>In April 2012, the US Food and Drug Administration issued a drug safety communication warning that the use of aliskiren with either ACE inhibitors or ARBs is contraindicated in patients with diabetes and should be avoided in patients with moderate to severe renal dysfunction (CrCl below 60 mL/min).<sup>8</sup> The aliskiren US prescribing information also reflects this recommendation and adds that this combination should generally be avoided in all patients.<sup>9</sup> Monitor serum potassium, serum creatinine, and blood pressure closely if the combination is used.</p> \n<p><b>Footnotes</b> </p>\n<p>1. American Diabetes Association. Standards of medical care in diabetes--2013. <i>Diabetes Care</i>. 2013;36(suppl 1:)S11-S66. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23264422\">[PubMed 23264422]</a></p>\n<p>2. Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. <i>Ann Intern Med</i>. 2008;148(1):30-48. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17984482\">[PubMed 17984482]</a></p>\n<p>3. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. <i>N Engl J Med</i>. 2008;358(15):1547-1559. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18378520\">[PubMed 18378520]</a></p>\n<p>4. AVOID Study Investigators, Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. <i>N Engl J Med</i>. 2008;358(23):2433-2446. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18525041\">[PubMed 18525041]</a></p>\n<p>5. Persson F, Lewis JB, Lewis EJ, Rossing P, Hollenberg NK, Parving HH. Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy. <i>Clin J Am Soc Nephrol</i>. 2011;6(5):1025-1031. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21350110\">[PubMed 21350110]</a></p>\n<p>6. Parving HH, Brenner BM, McMurray JJ, et al.; ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. <i>N Engl J Med</i>. 2012;367(23):2204-2213. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23121378\">[PubMed 23121378]</a></p>\n<p>7. Solomon SD, Shin SH, Shah A, et al.; Aliskiren Study in Post-MIPatients to Reduce Remodeling (ASPIRE) Investigators. Effect of the direct renin inhibitor aliskiren on left ventricular remodeling following myocardial infarction with systolic dysfunction. <i>Eur Heart J</i>. 2011;32(10):1227-1234. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21317148\">[PubMed 21317148]</a></p>\n<p>8. US Food and Drug Administration. FDA Drug Safety Communication: new warning and contraindication for blood pressure medicines containing aliskiren (Tekturna). Http://www.fda.gov/drugs/drugsafety/ucm300889.htm. Updated February 15, 2013. Accessed October 11, 2013.</p>\n<p>9. <i>Tekturna</i> (aliskiren) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; March 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6777":"<p><b>Title</b> Paraldehyde / CNS Depressants</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid combining paraldehyde with other CNS depressants due to the potential for enhanced CNS depressant effects.</p>\n<div>\n <p><b>CNS Depressants Interacting Members</b> Acrivastine, Afloqualone, Alcohol (Ethyl), Alfentanil, ALPRAZolam, Amisulpride, Amitriptyline, Amobarbital, Amoxapine, ARIPiprazole, ARIPiprazole Lauroxil, Asenapine, Baclofen, Benperidol, Benzhydrocodone, Bilastine, Blonanserin, Brexpiprazole, Brimonidine (Ophthalmic), Brivaracetam, Bromazepam, Bromperidol, Brompheniramine, Buclizine, Buprenorphine, BusPIRone, Butabarbital, Butalbital, Butorphanol, CarBAMazepine, Carbinoxamine, Cariprazine, Carisoprodol, Cetirizine (Systemic), Chloral Betaine, Chloral Hydrate, ChlordiazePOXIDE, Chlormethiazole, Chlorpheniramine, ChlorproMAZINE, Chlorzoxazone, Cinnarizine, Clemastine, CloBAZam, ClomiPRAMINE, ClonazePAM, CloNIDine, Clorazepate, Clothiapine, CloZAPine, Codeine, Cyclizine, Cyclobenzaprine, Cyproheptadine, Dantrolene, Desflurane, Desipramine, Desloratadine, Deutetrabenazine, Dexbrompheniramine, Dexchlorpheniramine, DiazePAM, Difenoxin, Dihydrocodeine, DimenhyDRINATE, Dimethindene (Systemic), DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Diphenoxylate, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Efavirenz, Emedastine (Systemic), Entacapone, Eperisone, Estazolam, Eszopiclone, Ethosuximide, Ethotoin, Ethyl Loflazepate, Etizolam, Ezogabine, Felbamate, FentaNYL, Fexofenadine, Flibanserin, Flunarizine, Flunitrazepam, Flupentixol, FluPHENAZine, Flurazepam, Fosphenytoin, Gabapentin, Gabapentin Enacarbil, Glutethimide, GuanFACINE, Haloperidol, Halothane, Heroin, HYDROcodone, HYDROmorphone, HydrOXYzine, Iloperidone, Imipramine, Isoflurane, Ketamine, Ketotifen (Systemic), LamoTRIgine, LevETIRAcetam, Levocetirizine, Levorphanol, Lofepramine, Loprazolam, Loratadine, LORazepam, Lormetazepam, Loxapine, Lurasidone, Maprotiline, Meclizine, Melitracen [INT], Meperidine, Meprobamate, Meptazinol, Mequitazine, Metaxalone, Methadone, Methocarbamol, Methohexital, Methotrimeprazine, Methoxyflurane, Methsuximide, Mianserin, Midazolam, Mirtazapine, Molindone, Morphine (Liposomal), Morphine (Systemic), Moxonidine, Nalbuphine, Nalfurafine, Nefopam, Nitrazepam, Nitrous Oxide, Nordazepam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Opium, Opium Tincture, Orphenadrine, Oxatomide, Oxazepam, Oxomemazine, OxyCODONE, OxyMORphone, Paliperidone, Paraldehyde, Paregoric, Pentazocine, PENTobarbital, Perampanel, Periciazine, Perphenazine, Pheniramine, PHENobarbital, Phenyltoloxamine, Phenytoin, Pholcodine, Pimozide, Pipamperone [INT], Pipotiazine, Pizotifen, Pomalidomide, Prazepam, Pregabalin, Primidone, Prochlorperazine, Promazine, Promethazine, Propofol, Protriptyline, Pyrilamine (Systemic), Quazepam, QUEtiapine, Ramelteon, Remifentanil, Reserpine, Rilmenidine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Secobarbital, Sevoflurane, Sodium Oxybate, Stiripentol, SUFentanil, Sulpiride, Suvorexant, Tapentadol, Tasimelteon, Temazepam, Tetrabenazine, Thalidomide, Thiopental, Thioridazine, Thiothixene, Thonzylamine, TiaGABine, TiZANidine, Tofisopam, Tolcapone, Topiramate, TraMADol, Triazolam, Trifluoperazine, Trimeprazine, Trimipramine, Triprolidine, Valerian, Vigabatrin, Zaleplon, Ziconotide, Ziprasidone, Zolpidem, Zonisamide, Zopiclone, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> According to the paraldehyde Canadian product monograph, concomitant administration of paraldehyde with other CNS depressants or alcohol should be avoided due to the potential risk of enhanced CNS depression.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Product monograph. Paraldehyde injection BP. Montreal, QC: Omega Laboratories Ltd., February 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6778":"<p><b>Title</b> Paraldehyde / Alcohol (Ethyl)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Alcohol (Ethyl) may enhance the CNS depressant effect of Paraldehyde. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Alcohol may potentiate the CNS depressant effects of paraldehyde, and should be avoided in paraldehyde-treated patients.</p> \n<p><b>Discussion</b> According to the paraldehyde Canadian product monograph, concomitant administration of paraldehyde with other CNS depressants or alcohol should be avoided due to the potential risk of enhanced CNS depression.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Product monograph. Paraldehyde injection BP. Montreal, QC: Omega Laboratories Ltd., February 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6779":"<p><b>Title</b> Paraldehyde / Disulfiram</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Disulfiram may increase the serum concentration of Paraldehyde. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid coadministration of disulfiram with paraldehyde due to a potential for increased paraldehyde and acetaldehyde concentrations.</p> \n<p><b>Discussion</b> In animal studies summarized in the paraldehyde Canadian product monograph, coadministration of disulfiram increased concentrations of paraldehyde and acetaldehyde in paraldehyde treated animals and potentiated paraldehyde pharmacodynamic effects.<sup>1,2</sup> Additionally, three published case reports describe transient psychosis developing in disulfiram-treated patients given paraldehyde.<sup>3</sup> <br><br>The suspected mechanism of pharmacokinetic interaction between these drugs is disulfiram inhibition of acetaldehyde dehydrogenase mediated metabolism of the paraldehyde metabolite acetaldehyde, and possibly of paraldehyde itself (metabolism of the parent molecule is poorly understood but may involve the cytochrome P-450 system).<sup>1,4</sup> The mechanism by which this combination could increase risk of psychosis is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Product monograph. Paraldehyde injection BP. Montreal, QC: Omega Laboratories Ltd., February 2011.</p>\n<p>2. Keplinger ML and Wells JA, “The Effect of Disulfiram on the Action and Metabolism of Paraldehyde,” <i>J Pharmacol Exp Ther</i>, 1957, 119(1):19-25. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=13417055\">[PubMed 13417055]</a></p>\n<p>3. Christie GL, “Three Cases of Transient Confusional Psychosis in Patients Receiving Con-Current Antabuse and Paraldehyde Therapy,” <i>Med J Aust</i>, 1956, 1(19):789-91. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=13333431\">[PubMed 13333431]</a></p>\n<p>4. Zaleska MM and Gessner PK, “Metabolism of Paraldehyde to Acetaldehyde in Liver Microsomes. Evidence for the Involvement of Cytochrome P-450,” <i>Biochem Pharmacol</i>, 1983, 32(24):3749-54. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6661251\">[PubMed 6661251]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6787":"<p><b>Title</b> Vitamin K Antagonists / Sulfonylureas</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Sulfonylureas may enhance the anticoagulant effect of Vitamin K Antagonists. Vitamin K Antagonists may enhance the hypoglycemic effect of Sulfonylureas. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Patients who have been receiving sulfonylureas should be cautioned that there may be a greater risk for hypoglycemia after initiation of warfarin and counseled on what to do if they experience any signs/symptoms of hypoglycemia. Closer monitoring of both glycemic control and anticoagulant response may be warranted in patients using this combination.</p>\n<div>\n <p><b>Sulfonylureas Interacting Members</b> ChlorproPAMIDE, Gliclazide, Glimepiride*, GlipiZIDE*, GlyBURIDE, TOLAZamide, TOLBUTamide</p>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin*</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> Concurrent use of warfarin was associated with increased odds of hospital admission or emergency department (ED) visit related to hypoglycemia [adjusted OR=1.22 (95% CI: 1.05 to 1.42)] in a retrospective cohort study of subjects 65 years-of-age or older with type 2 diabetes who had received either glipizide or glimepiride (n=465,918).<sup>1</sup> Initial users of warfarin and patients 65 to 74 years-of-age were identified as higher risk groups. The combination of warfarin with glipizide or glimepiride was also associated with an increased odds for admissions/ED visits secondary to fall-related fractures or altered consciousness [adjusted OR for hypoglycemia, fall-related fracture, or altered consciousness = 1.38 (1.33 to 1.42)].<br><br>The specific mechanism for this potential interaction is uncertain, although increased concentrations of unbound sulfonylureas due to displacement of sulfonylureas from their protein binding sites by warfarin and/or competitive inhibition of CYP2C9-mediated sulfonylurea metabolism have been proposed as possible mechanisms.<sup>1,2</sup> In vitro, warfarin decreased the binding of tolbutamide to human albumin by 13-fold and decreased glyburide binding by approximately 40%.<sup>3</sup> Acidic drugs such as warfarin would be expected to displace ionic-binding sulfonylureas (e.g., tolbutamide) from serum proteins to a much greater extent than non-ionic binding sulfonylureas (e.g., glyburide).<sup>2</sup> It has been demonstrated, however, that protein binding displacement generally has very little effect on drug exposure, except for drugs with high liver extraction ratios administered via a non-oral route.<sup>4</sup><br><br>Additionally, a single case report describes a warfarin-maintained patient whose INR became elevated during glyburide treatment.<sup>5</sup> The patient's INR returned rapidly to baseline following glyburide discontinuation. Competition for hepatic metabolic enzymes and/or protein binding displacement may be considered possible mechanisms for this reported interaction as well.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Romley JA, Gong C, Jena AB, Goldman DP, Williams B, Peters A. Association between use of warfarin with common sulfonylureas and serious hypoglycemic events: retrospective cohort analysis. <i>BMJ</i>. 2015;351:h6223. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26643108\">[PubMed 26643108]</a></p>\n<p>2. Prescribing information. Micronase (glyburide). New York, NY: Pfizer Inc; May 2010.</p>\n<p>3. Brown KF, Crooks MJ. Displacement of tolbutamide, glibencalmide and chlorpropamide from serum albumin by anionic drugs. <i>Biochem Pharmacol</i>. 1976;25(10):1175-1178. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=820348\">[PubMed 820348]</a></p>\n<p>4. Benet LZ, Hoener B. Changes in plasma protein binding have little clinical relevance. <i>Clin Pharmacol Ther</i>. 2002;71(3):115-121. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11907485\">[PubMed 11907485]</a></p>\n<p>5. Jassal SV. Warfarin potentiated by proguanil. <i>BMJ</i>. 1991;303(6805):789. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1932962\">[PubMed 1932962]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6788":"<p><b>Title</b> Ifosfamide / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Ifosfamide. CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Use of a strong CYP3A4 inducer may increase metabolism of ifosfamide, potentially increasing or decreasing ifosfamide therapeutic effects as well as increasing the risk of some toxicities (e.g., nephrotoxicity, neurotoxicity). Monitor patients closely for clinical response and toxicity, and adjust dose as needed.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> Exposure to the active 4-hydroxyifosfamide metabolite of ifosfamide was reduced by an average of 11% with the strong CYP3A4 inducer rifampin in a study of 8 volunteers with incurable malignancies who were receiving palliative ifosfamide (3 g/m<sup>2</sup> given by 24-hour continuous infusion) with or without concurrent rifampin (300 mg orally twice/day for 6 days, starting 3 days prior to the ifosfamide).<sup>1</sup> Exposure to the inactive 2- and 3-dechloroethylifosfamide metabolites, which are themselves inactive but potentially contribute to neurotoxicity via production of chloroacetaldehyde, was reduced by an average of 32% and 72%, respectively. Overall clearance of the parent ifosfamide was increased by an average of 102%. These findings are generally consistent with, but of a lower magnitude than those of an in vitro study in human hepatocytes that reported ifosfamide 4-hydroxylation that was 200% to 400% of control values.<sup>2</sup><br><br>The clinical significance of these findings is uncertain, but the slight decrease in 4-hydroxyifosfamide exposure, without any substantially greater decrease in exposure to the 2- and 3-dechloroethyl metabolites suggests this interaction may negatively impact effectiveness without a clear beneficial effect on toxicity risk. Per ifosfamide prescribing information, coadministration of ifosfamide with CYP3A4 inducers, such as rifampin, may increase the rate of metabolism of ifosfamide to its active alkylating metabolites.<sup>3</sup> This could theoretically increase ifosfamide therapeutic effects as well as the likelihood of some toxicities (e.g., nephrotoxicity, neurotoxicity).<sup>1,3</sup><br><br>The mechanism for this apparent interaction is likely rifampin induction of both CYP3A4 and CYP2B6, resulting in enhanced clearance of ifosfamide to both its 4-hydroxy and its 2- and 3-dechloroethyl metabolites.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kerbusch T, Jansen RL, Mathot RA, et al. Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin. <i>Clin Pharmacol Ther</i>. 2001;70(2):132-141. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11503007\">[PubMed 11503007]</a></p>\n<p>2. Chang TK, Yu L, Maurel P, Waxman DJ. Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. <i>Cancer Res</i>. 1997;57(10):1946-1954. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9157990\">[PubMed 9157990]</a></p>\n<p>3. <i>Ifex</i> (ifosfamide) [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; March 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6789":"<p><b>Title</b> Ifosfamide / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Use of a CYP3A4 inhibitor may decrease metabolism of ifosfamide, potentially reducing ifosfamide therapeutic effects as well as altering the risk of some toxicities (e.g., nephrotoxicity, neurotoxicity).</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> Exposure to the active 4-hydroxyifosfamide metabolite of ifosfamide was reduced by an average of 30% with the strong CYP3A4 inhibitor ketoconazole in a study of 8 volunteers with incurable malignancies who were receiving palliative ifosfamide (3 g/m<sup>2</sup> given by 24-hour continuous infusion) with or without concurrent ketoconazole (200 mg orally twice/day for 4 days, starting 1 day prior to the ifosfamide).<sup>1</sup> Exposure to the inactive 2- and 3-dechloroethylifosfamide (2DCE and 3DCE, respectively) metabolites, which are themselves inactive but potentially contribute to neurotoxicity via production of chloroacetaldehyde, was variably altered, with exposure to 2DCE increased by an average of 23% and exposure to 3DCE decreased by 6%. Overall clearance of the parent ifosfamide was decreased by an average of 11%.<br><br>The clinical significance of these findings is uncertain, but per ifosfamide prescribing information, coadministration of ifosfamide with CYP3A4 inhibitors may decrease metabolism of ifosfamide to its active alkylating metabolites.<sup>2</sup> This could theoretically decrease ifosfamide therapeutic effects as well as altering the risk for some toxicities (e.g., nephrotoxicity, neurotoxicity).<br><br>The mechanism for this apparent interaction is likely inhibition of CYP3A4, resulting in decreased clearance of ifosfamide to both its 4-hydroxy and its 2- and 3-dechloroethyl metabolites.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kerbusch T, Jansen RL, Mathot RA, et al. Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin. <i>Clin Pharmacol Ther</i>. 2001;70(2):132-141. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11503007\">[PubMed 11503007]</a></p>\n<p>2. <i>Ifex</i> (ifosfamide) [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; March 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6790":"<p><b>Title</b> Ifosfamide / CYP3A4 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Use of a CYP3A4 inhibitor may decrease metabolism of ifosfamide, potentially reducing ifosfamide therapeutic effects as well as the risk of some toxicities (eg, nephrotoxicity, neurotoxicity).</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Moderate) Interacting Members</b> Aprepitant, Conivaptan, Crizotinib, DilTIAZem, Dronedarone, Erythromycin (Systemic), Fluconazole, Fosamprenavir, Grapefruit Juice, Imatinib, Isavuconazonium Sulfate, Letermovir, Netupitant, Nilotinib, Ribociclib, Schisandra, Verapamil</p>\n</div> \n<p><b>Discussion</b> In a clinical study of 8 patients with malignancies that were considered incurable, coadministration of the strong CYP3A inhibitor ketoconazole (200 mg orally twice daily for 4 days, beginning 1 day before ifosfamide) increased ifosfamide (3 g/m2 intravenously over 24 hours) AUC by 14%, increased AUC of its 2-dechloroethylifosfamide metabolite by 23%, and decreased AUCs of the metabolites 3-dechloroethylifosfamide and 4-hydroxyifosfamide by 6% and 30%, respectively.<sup>1</sup> Of these findings, only the increase in 2-dechloroethylifosfamide AUC was statistically significant.<br><br>Per ifosfamide prescribing information, coadministration of ifosfamide with CYP3A4 inhibitors may decrease metabolism of ifosfamide to its active alkylating metabolites.<sup>2</sup> This could theoretically decrease ifosfamide therapeutic effects as well as the likelihood of some toxicities (eg, nephrotoxicity, neurotoxicity).<sup>2,3</sup> The ifosfamide prescribing information warns of its interaction potential not only with strong CYP3A inhibitors such as ketoconazole, but also with moderate 3A4 inhibitors. <br><br>Aprepitant/fosaprepitant are listed among the moderate CYP3A4 inhibitors, but the aprepitant/fosaprepitant prescribing information cites post-marketing reports of neurotoxicity associated with concurrent use of aprepitant and ifosfamide.<sup>4,5</sup> Aprepitant has both CYP3A4-inhibition and CYP3A4-induction effects and increased neurotoxicity is more consistent with CYP3A4 induction. See ifosfamide/aprepitant or ifosfamide/fosaprepitant monographs for a full discussion on these specific potential interactions.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kerbusch T, Jansen RL, Mathot RA, et al. Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin. <i>Clin Pharmacol Ther</i>. 2001;70(2):132-141. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11503007\">[PubMed 11503007]</a></p>\n<p>2. <i>Ifex</i> (ifosfamide) [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; March 2012.</p>\n<p>3. McCune JS, Risler LJ, Phillips BR, Thummel KE, Blough D, Shen DD. Contribution of CYP3A5 to hepatic and renal ifosfamide N-dechloroethylation. <i>Drug Metab Dispos</i>. 2005;33(7):1074-1081. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15821045\">[PubMed 15821045]</a></p>\n<p>4. <i>Emend</i> (aprepitant) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; August 2014.</p>\n<p>5. <i>Emend</i> (fosaprepitant dimeglumine) [prescribing information]. Whitehouse Station, NJ: Merck&amp; Co Inc; August 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6791":"<p><b>Title</b> Ifosfamide / Busulfan</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Busulfan may enhance the adverse/toxic effect of Ifosfamide. Specifically, the risk of hemorrhagic cystitis may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Busulfan may increase the risk of hemorrhagic cystitis during ifosfamide treatment. Follow standard practices for hydration, mesna administration, and use of urinalysis to guide dose administration/withholding decisions.</p> \n<p><b>Discussion</b> According to ifosfamide prescribing information, busulfan may increase the risk of hemorrhagic cystitis during ifosfamide treatment.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Ifex (ifosfamide). Deerfield, IL: Baxter Healthcare Corporation, 3/2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6792":"<p><b>Title</b> Zolpidem / FluvoxaMINE</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> FluvoxaMINE may enhance the CNS depressant effect of Zolpidem. FluvoxaMINE may increase the serum concentration of Zolpidem. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients closely for evidence of an exaggerated or excessive response to zolpidem when used together with fluvoxamine. A reduced dose of zolpidem may be needed.</p> \n<p><b>Discussion</b> The zolpidem AUC was an average of 155% higher with concurrent fluvoxamine (100 mg/day) in a study of healthy volunteers who received zolpidem (5 mg) with or without fluvoxamine.<sup>1</sup> The zolpidem maximum serum concentration (Cmax) was also an average of 20% higher, and the average zolpidem half-life was 127% higher (5 hrs vs. 2.2 hrs).<sup>1</sup> A published case report also suggests the existence of a clinically significant interaction between zolpidem and fluvoxamine, describing hallucinations and amnesia in a patient receiving this combination.<sup>2</sup><br><br>Zolpidem prescribing information states that fluvoxamine is likely to inhibit the metabolic pathways responsible for zolpidem metabolism, potentially leading to an increase in zolpidem exposure.<sup>3</sup><br><br>The mechanism(s) for this interaction are uncertain, though both pharmacokinetic and pharmacodynamic mechanisms may contribute. Zolpidem appears to be metabolized primarily via CYP3A with a modest contribution by CYP2C9 and CYP1A2 and minor involvement of CYP2D6 and CYP2C19.<sup>4,5</sup> Fluvoxamine is a strong inhibitor of CYP1A2 and CYP2C19, but only a relatively weak inhibitor of CYP3A, CYP2C9, and CYP2D6. As a result, fluvoxamine-mediated inhibition of zolpidem is possible, but would not be predicted to result in as large of a pharmacokinetic effect as observed, suggesting either the existence of some other possible mechanism or that the findings observed in this single study are not representative of what would be observed in most patients. Considering that both zolpidem and fluvoxamine are CNS-active drugs and are both capable of causing sedation and other CNS effects, an additional interaction mechanism where these agents cause additive/synergistic CNS effects is also possible (and may be magnified if there is a pharmacokinetic interaction similar to what has been observed).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Vlase L, Popa A, Neag M, et al, “Effect of Fluvoxamine on the Pharmokinetics of Zolpidem: A Two-Treatment Period Study in Healthy Volunteers,”<i>Clin Exp Pharmacol Physiol</i>, 2012, 39(1):9-12. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21985609\">[PubMed 21985609]</a></p>\n<p>2. Kito S, Koga Y, “Visual Hallucinations and Amnesia Associated with Zolpidem Triggered by Fluvoxamine: A Possible Interaction,” <i>Int Psychogeriatr</i>, 2006, 18(4):749-51. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17026779\">[PubMed 17026779]</a></p>\n<p>3. Ambien (zolpidem) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC, August 2016.</p>\n<p>4. Von Moltke LL, Greenblatt DJ, Granda BW, et al, “Zolpidem Metabolism In Vitro: Responsible Cytochromes, Chemical Inhibitors, and In Vivo Correlations,” <i>Br J Clin Pharmacol</i>, 1999, 48(1):89-97. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10383565\">[PubMed 10383565]</a> </p>\n<p>5. Pichard L, Gillet G, Bonfils C, et al, “Oxidative Metabolism of Zolpidem by Human Liver Cytochrome P450S,” <i>Drug Metab Dispos</i>, 1995, 23(11):1253-62. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8591727\">[PubMed 8591727]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6796":"<p><b>Title</b> Ivermectin (Systemic) / Azithromycin (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Azithromycin (Systemic) may increase the serum concentration of Ivermectin (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Note that the use of this combination may increase ivermectin concentrations and the risk for ivermectin-associated adverse effects. Monitor patients closely for evidence of ivermectin adverse effects, which vary according to clinical use but may include itching/rash, dizziness, diarrhea, and nausea.</p> \n<p><b>Discussion</b> The ivermectin AUC and maximum serum concentration (Cmax) were an average of 31% and 27% higher, respectively, with concurrent azithromycin in a study of 18 healthy volunteers who received single doses of ivermectin (200 mcg/kg) and albendazole (400 mg) with or without azithromycin (500 mg).<sup>1</sup><br><br>Considering that ivermectin is not highly sensitive to CYP3A induction or inhibition and that azithromycin is not a strong CYP3A inhibitor, the specific mechanism for this apparent interaction is unclear. Of note, a series of computer simulations based on the findings of this interaction study suggested that azithromycin may increase the bioavailability of ivermectin in a subset of patients (estimated 37% increase in bioavailability in those individuals),<sup>2</sup> though whether this increase in bioavailability is due to CYP3A and/or p-glycoprotein inhibition is uncertain. Similarly, how to identify the specific individuals sensitive to this interaction is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Amsden GW, Gregory TB, Michalak CA, et al, “Pharmacokinetics of Azithromycin and the Combination of Ivermectin and Albendazole when Administered Alone and Concurrently in Healthy Volunteers,” <i>Am J Trop Med Hyg</i>, 2007, 76(6):1153-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17556628\">[PubMed 17556628]</a></p>\n<p>2. El-Tahtawy A, Glue P, Andrews EN, et al, “The Effect of Azithromycin on Ivermectin Pharmacokinetics--A Population Pharmacokinetic Model Analysis,” <i>PLoS Negl Trop Dis</i>, 2008, 2(5):e236. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18478051\">[PubMed 18478051]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6798":"<p><b>Title</b> QuiNINE / Lopinavir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Lopinavir may decrease the serum concentration of QuiNINE. This effect has been seen with lopinavir/ritonavir. The individual contributions of lopinavir and ritonavir to this effect are unclear. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Avoid concurrent use of quinine with lopinavir/ritonavir.</p> \n<p><b>Discussion</b> In a clinical study of 13 healthy volunteers, the quinine (648 mg quinine sulfate single oral dose) AUC and maximum serum concentration (Cmax) decreased by around 50% when given on the 12th day of lopinavir/ritonavir (400/100 mg twice daily).<sup>1</sup> 3-hydroxyquinine AUC and Cmax decreased by approximately 70%.<sup>1</sup> In a previous clinical study of 10 healthy volunteers, the average AUC and Cmax of quinine actually increased approximately 4-fold when quinine (600 mg quinine sulfate single oral dose) was given on the 8th day of ritonavir administration (200 mg every 12 hours).<sup>2</sup><br><br>The specific mechanisms of these interactions are uncertain, as is the reason for the differing results seen with ritonavir and lopinavir/ritonavir. Quinine is a substrate of CYP3A4 and P-glycoprotein, both of which are inhibited by lopinavir and ritonavir. Ritonavir also induces CYP3A. Quinine prescribing information recommends avoiding concurrent use of ritonavir and quinine.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Nyunt MM, Lu Y, Yu Q, et al, “Effects of Ritonavir-Boosted Lopinavir on the Pharmacokinetics of Quinine,” <i>Clin Pharmacol Ther</i>, 2012, 91(5):889-95. Epub. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22472986\">[PubMed 22472986]</a></p>\n<p>2. Soyinka JO, Onyeji CO, Omoruyi SI, et al, “Pharmacokinetic Interactions Between Ritonavir and Quinine in Healthy Volunteers Following Concurrent Administration,” <i>Br J Clin Pharmacol</i>, 2010, 69(3):262-70. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20233197\">[PubMed 20233197]</a></p>\n<p>3. Prescribing information. Qualaquin (quinidine). Philadelphia, PA: AR Scientific, Inc., 4/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","6799":"<p><b>Title</b> Azelastine (Nasal) / CNS Depressants</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid combining nasal azelastine with other CNS depressants due to the potential for enhanced CNS depressant effects.</p>\n<div>\n <p><b>CNS Depressants Interacting Members</b> Acrivastine, Afloqualone, Alcohol (Ethyl), Alfentanil, ALPRAZolam, Amisulpride, Amitriptyline, Amobarbital, Amoxapine, ARIPiprazole, ARIPiprazole Lauroxil, Asenapine, Baclofen, Benperidol, Benzhydrocodone, Bilastine, Blonanserin, Brexpiprazole, Brimonidine (Ophthalmic), Brivaracetam, Bromazepam, Bromperidol, Brompheniramine, Buclizine, Buprenorphine, BusPIRone, Butabarbital, Butalbital, Butorphanol, CarBAMazepine, Carbinoxamine, Cariprazine, Carisoprodol, Cetirizine (Systemic), Chloral Betaine, Chloral Hydrate, ChlordiazePOXIDE, Chlormethiazole, Chlorpheniramine, ChlorproMAZINE, Chlorzoxazone, Cinnarizine, Clemastine, CloBAZam, ClomiPRAMINE, ClonazePAM, CloNIDine, Clorazepate, Clothiapine, CloZAPine, Codeine, Cyclizine, Cyclobenzaprine, Cyproheptadine, Dantrolene, Desflurane, Desipramine, Desloratadine, Deutetrabenazine, Dexbrompheniramine, Dexchlorpheniramine, DiazePAM, Difenoxin, Dihydrocodeine, DimenhyDRINATE, Dimethindene (Systemic), DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Diphenoxylate, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Efavirenz, Emedastine (Systemic), Entacapone, Eperisone, Estazolam, Eszopiclone, Ethosuximide, Ethotoin, Ethyl Loflazepate, Etizolam, Ezogabine, Felbamate, FentaNYL, Fexofenadine, Flibanserin, Flunarizine, Flunitrazepam, Flupentixol, FluPHENAZine, Flurazepam, Fosphenytoin, Gabapentin, Gabapentin Enacarbil, Glutethimide, GuanFACINE, Haloperidol, Halothane, Heroin, HYDROcodone, HYDROmorphone, HydrOXYzine, Iloperidone, Imipramine, Isoflurane, Ketamine, Ketotifen (Systemic), LamoTRIgine, LevETIRAcetam, Levocetirizine, Levorphanol, Lofepramine, Loprazolam, Loratadine, LORazepam, Lormetazepam, Loxapine, Lurasidone, Maprotiline, Meclizine, Melitracen [INT], Meperidine, Meprobamate, Meptazinol, Mequitazine, Metaxalone, Methadone, Methocarbamol, Methohexital, Methotrimeprazine, Methoxyflurane, Methsuximide, Mianserin, Midazolam, Mirtazapine, Molindone, Morphine (Liposomal), Morphine (Systemic), Moxonidine, Nalbuphine, Nalfurafine, Nefopam, Nitrazepam, Nitrous Oxide, Nordazepam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Opium, Opium Tincture, Orphenadrine, Oxatomide, Oxazepam, Oxomemazine, OxyCODONE, OxyMORphone, Paliperidone, Paraldehyde, Paregoric, Pentazocine, PENTobarbital, Perampanel, Periciazine, Perphenazine, Pheniramine, PHENobarbital, Phenyltoloxamine, Phenytoin, Pholcodine, Pimozide, Pipamperone [INT], Pipotiazine, Pizotifen, Pomalidomide, Prazepam, Pregabalin, Primidone, Prochlorperazine, Promazine, Promethazine, Propofol, Protriptyline, Pyrilamine (Systemic), Quazepam, QUEtiapine, Ramelteon, Remifentanil, Reserpine, Rilmenidine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Secobarbital, Sevoflurane, Sodium Oxybate, Stiripentol, SUFentanil, Sulpiride, Suvorexant, Tapentadol, Tasimelteon, Temazepam, Tetrabenazine, Thalidomide, Thiopental, Thioridazine, Thiothixene, Thonzylamine, TiaGABine, TiZANidine, Tofisopam, Tolcapone, Topiramate, TraMADol, Triazolam, Trifluoperazine, Trimeprazine, Trimipramine, Triprolidine, Valerian, Vigabatrin, Zaleplon, Ziconotide, Ziprasidone, Zolpidem, Zonisamide, Zopiclone, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> According to the U.S. prescribing information for several nasal azelastine products, concomitant administration of nasal azelastine with other CNS depressants or alcohol should be avoided due to the potential risk of enhanced CNS depression.<sup>1,2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Dymista (azelastine/fluticasone). Somerset, NJ: Meda Pharmaceuticals Inc., 4/2012.</p>\n<p>2. Prescribing information. Astelin (azelastine). Somerset, NJ: Meda Pharmaceuticals Inc., 1/2012.</p>\n<p>3. Prescribing information. Astepro (azelastine). Somerset, NJ: Meda Pharmaceuticals Inc., 8/2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}